JPWO2003085119A1 - 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法 - Google Patents

抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法 Download PDF

Info

Publication number: JPWO2003085119A1
Authority: JP; Japan
Prior art keywords: antibody; cell; cells; fucose; sugar chain
Prior art date: 2002-04-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2003582297A

Other languages

English (en)

Japanese (ja)

Inventor

中村　和靖

和靖中村

設楽　研也

研也設楽

Original Assignee

協和醗酵工業株式会社

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-09

Filing date

2003-04-09

Publication date

2005-08-11

2003-04-09 Application filed by 協和醗酵工業株式会社 filed Critical 協和醗酵工業株式会社

2005-08-11 Publication of JPWO2003085119A1 publication Critical patent/JPWO2003085119A1/ja

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 530
239000000203 mixture Substances 0.000 title claims abstract description 193
102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 title claims abstract description 121
230000027455 binding Effects 0.000 title claims abstract description 77
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 title claims abstract description 43
230000002708 enhancing effect Effects 0.000 title claims description 7
235000000346 sugar Nutrition 0.000 claims abstract description 274
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 90
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims abstract description 90
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims abstract description 89
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims abstract description 88
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims abstract description 88
229950006780 n-acetylglucosamine Drugs 0.000 claims abstract description 88
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims abstract description 87
108090001090 Lectins Proteins 0.000 claims abstract description 73
102000004856 Lectins Human genes 0.000 claims abstract description 73
239000002523 lectin Substances 0.000 claims abstract description 73
238000004519 manufacturing process Methods 0.000 claims abstract description 70
229930182474 N-glycoside Natural products 0.000 claims abstract description 69
108091006020 Fc-tagged proteins Proteins 0.000 claims abstract description 61
235000021310 complex sugar Nutrition 0.000 claims abstract description 47
230000001472 cytotoxic effect Effects 0.000 claims abstract description 16
230000001419 dependent effect Effects 0.000 claims abstract description 15
210000004027 cell Anatomy 0.000 claims description 583
108090000623 proteins and genes Proteins 0.000 claims description 285
241000282414 Homo sapiens Species 0.000 claims description 194
LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 claims description 169
LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 claims description 169
108090000790 Enzymes Proteins 0.000 claims description 138
102000004190 Enzymes Human genes 0.000 claims description 131
102000004169 proteins and genes Human genes 0.000 claims description 125
230000000694 effects Effects 0.000 claims description 115
241000196324 Embryophyta Species 0.000 claims description 59
210000004102 animal cell Anatomy 0.000 claims description 58
239000000427 antigen Substances 0.000 claims description 50
108091007433 antigens Proteins 0.000 claims description 50
102000036639 antigens Human genes 0.000 claims description 50
206010035226 Plasma cell myeloma Diseases 0.000 claims description 44
201000000050 myeloid neoplasm Diseases 0.000 claims description 44
241000238631 Hexapoda Species 0.000 claims description 37
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 37
238000012258 culturing Methods 0.000 claims description 35
210000001519 tissue Anatomy 0.000 claims description 35
239000002773 nucleotide Substances 0.000 claims description 30
125000003729 nucleotide group Chemical group 0.000 claims description 30
230000004048 modification Effects 0.000 claims description 27
238000012986 modification Methods 0.000 claims description 27
230000003834 intracellular effect Effects 0.000 claims description 26
239000012634 fragment Substances 0.000 claims description 22
210000004408 hybridoma Anatomy 0.000 claims description 22
210000001671 embryonic stem cell Anatomy 0.000 claims description 20
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 19
230000002829 reductive effect Effects 0.000 claims description 18
238000003786 synthesis reaction Methods 0.000 claims description 17
230000015572 biosynthetic process Effects 0.000 claims description 16
238000012360 testing method Methods 0.000 claims description 16
241000699673 Mesocricetus auratus Species 0.000 claims description 12
108020001507 fusion proteins Proteins 0.000 claims description 12
102000037865 fusion proteins Human genes 0.000 claims description 12
108010034897 lentil lectin Proteins 0.000 claims description 12
241000699802 Cricetulus griseus Species 0.000 claims description 11
238000011088 calibration curve Methods 0.000 claims description 11
210000001672 ovary Anatomy 0.000 claims description 10
108091000699 pea lectin Proteins 0.000 claims description 10
235000010749 Vicia faba Nutrition 0.000 claims description 9
240000006677 Vicia faba Species 0.000 claims description 9
235000002098 Vicia faba var. major Nutrition 0.000 claims description 9
208000032839 leukemia Diseases 0.000 claims description 8
210000005084 renal tissue Anatomy 0.000 claims description 8
210000002288 golgi apparatus Anatomy 0.000 claims description 7
230000004927 fusion Effects 0.000 claims description 3
108090000368 Fibroblast growth factor 8 Proteins 0.000 claims description 2
102000003956 Fibroblast growth factor 8 Human genes 0.000 claims description 2
230000001965 increasing effect Effects 0.000 abstract description 14
238000009739 binding Methods 0.000 abstract description 10
108020004414 DNA Proteins 0.000 description 142
235000018102 proteins Nutrition 0.000 description 106
239000002609 medium Substances 0.000 description 90
239000013604 expression vector Substances 0.000 description 86
101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 82
125000003275 alpha amino acid group Chemical group 0.000 description 78
239000002299 complementary DNA Substances 0.000 description 76
108010078791 Carrier Proteins Proteins 0.000 description 72
239000013598 vector Substances 0.000 description 72
102000014914 Carrier Proteins Human genes 0.000 description 65
241000699666 Mus <mouse, genus> Species 0.000 description 37
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 35
239000000243 solution Substances 0.000 description 35
241001465754 Metazoa Species 0.000 description 34
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 33
239000012228 culture supernatant Substances 0.000 description 31
238000006243 chemical reaction Methods 0.000 description 30
108091034117 Oligonucleotide Proteins 0.000 description 29
108020004999 messenger RNA Proteins 0.000 description 29
238000010369 molecular cloning Methods 0.000 description 29
238000004458 analytical method Methods 0.000 description 26
239000012636 effector Substances 0.000 description 25
238000002360 preparation method Methods 0.000 description 25
230000014509 gene expression Effects 0.000 description 24
235000001014 amino acid Nutrition 0.000 description 22
239000013612 plasmid Substances 0.000 description 22
230000009261 transgenic effect Effects 0.000 description 22
101710203794 GDP-fucose transporter Proteins 0.000 description 21
150000001413 amino acids Chemical class 0.000 description 21
206010028980 Neoplasm Diseases 0.000 description 20
241000700159 Rattus Species 0.000 description 19
235000013601 eggs Nutrition 0.000 description 19
239000000523 sample Substances 0.000 description 19
241000588724 Escherichia coli Species 0.000 description 18
241000700605 Viruses Species 0.000 description 18
238000005516 engineering process Methods 0.000 description 18
230000006870 function Effects 0.000 description 18
108010062427 GDP-mannose 4,6-dehydratase Proteins 0.000 description 17
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 17
201000011510 cancer Diseases 0.000 description 17
238000010367 cloning Methods 0.000 description 17
238000000746 purification Methods 0.000 description 17
102000005962 receptors Human genes 0.000 description 17
108020003175 receptors Proteins 0.000 description 17
108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
230000001900 immune effect Effects 0.000 description 16
239000003814 drug Substances 0.000 description 15
239000012091 fetal bovine serum Substances 0.000 description 15
238000002965 ELISA Methods 0.000 description 14
102000040811 transporter activity Human genes 0.000 description 14
108090000288 Glycoproteins Proteins 0.000 description 13
102000003886 Glycoproteins Human genes 0.000 description 13
241000699670 Mus sp. Species 0.000 description 13
238000013459 approach Methods 0.000 description 13
210000000349 chromosome Anatomy 0.000 description 13
238000011160 research Methods 0.000 description 13
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 12
238000004520 electroporation Methods 0.000 description 12
238000003018 immunoassay Methods 0.000 description 12
102100037047 Fucose-1-phosphate guanylyltransferase Human genes 0.000 description 11
101001029296 Homo sapiens Fucose-1-phosphate guanylyltransferase Proteins 0.000 description 11
JMVSBFJBMXQNJW-GIXZANJISA-N all-trans-pentaprenyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O JMVSBFJBMXQNJW-GIXZANJISA-N 0.000 description 11
210000000170 cell membrane Anatomy 0.000 description 11
210000001161 mammalian embryo Anatomy 0.000 description 11
230000035772 mutation Effects 0.000 description 11
108091008146 restriction endonucleases Proteins 0.000 description 11
239000000126 substance Substances 0.000 description 11
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 10
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
230000009368 gene silencing by RNA Effects 0.000 description 10
238000010353 genetic engineering Methods 0.000 description 10
230000012010 growth Effects 0.000 description 10
239000001963 growth medium Substances 0.000 description 10
238000009396 hybridization Methods 0.000 description 10
239000013615 primer Substances 0.000 description 10
238000012552 review Methods 0.000 description 10
241000701447 unidentified baculovirus Species 0.000 description 10
101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 9
102100024952 Protein CBFA2T1 Human genes 0.000 description 9
239000003242 anti bacterial agent Substances 0.000 description 9
229940088710 antibiotic agent Drugs 0.000 description 9
229940079593 drug Drugs 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
230000003248 secreting effect Effects 0.000 description 9
235000002639 sodium chloride Nutrition 0.000 description 9
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
108090000994 Catalytic RNA Proteins 0.000 description 8
102000053642 Catalytic RNA Human genes 0.000 description 8
230000004544 DNA amplification Effects 0.000 description 8
108010073807 IgG Receptors Proteins 0.000 description 8
108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
229920002684 Sepharose Polymers 0.000 description 8
230000000259 anti-tumor effect Effects 0.000 description 8
238000010276 construction Methods 0.000 description 8
239000003623 enhancer Substances 0.000 description 8
238000002744 homologous recombination Methods 0.000 description 8
230000006801 homologous recombination Effects 0.000 description 8
231100000350 mutagenesis Toxicity 0.000 description 8
210000000822 natural killer cell Anatomy 0.000 description 8
239000000047 product Substances 0.000 description 8
108091092562 ribozyme Proteins 0.000 description 8
239000000758 substrate Substances 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
108010021468 Fc gamma receptor IIA Proteins 0.000 description 7
102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 7
238000005119 centrifugation Methods 0.000 description 7
238000004587 chromatography analysis Methods 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
210000002540 macrophage Anatomy 0.000 description 7
210000001616 monocyte Anatomy 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
101710186708 Agglutinin Proteins 0.000 description 6
208000024172 Cardiovascular disease Diseases 0.000 description 6
102000011632 Caseins Human genes 0.000 description 6
108010076119 Caseins Proteins 0.000 description 6
241000701022 Cytomegalovirus Species 0.000 description 6
101710146024 Horcolin Proteins 0.000 description 6
206010020751 Hypersensitivity Diseases 0.000 description 6
102100040648 L-fucose kinase Human genes 0.000 description 6
101710189395 Lectin Proteins 0.000 description 6
101710179758 Mannose-specific lectin Proteins 0.000 description 6
101710150763 Mannose-specific lectin 1 Proteins 0.000 description 6
101710150745 Mannose-specific lectin 2 Proteins 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
239000004698 Polyethylene Substances 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 6
238000012300 Sequence Analysis Methods 0.000 description 6
230000004913 activation Effects 0.000 description 6
239000000910 agglutinin Substances 0.000 description 6
-1 ammonium phosphate Chemical class 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
238000007796 conventional method Methods 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000000284 extract Substances 0.000 description 6
108010083136 fucokinase Proteins 0.000 description 6
238000010363 gene targeting Methods 0.000 description 6
238000002955 isolation Methods 0.000 description 6
244000005700 microbiome Species 0.000 description 6
210000000440 neutrophil Anatomy 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
150000007523 nucleic acids Chemical class 0.000 description 6
150000007524 organic acids Chemical class 0.000 description 6
229920005989 resin Polymers 0.000 description 6
239000011347 resin Substances 0.000 description 6
238000012216 screening Methods 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
238000012546 transfer Methods 0.000 description 6
230000032258 transport Effects 0.000 description 6
241000282693 Cercopithecidae Species 0.000 description 5
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 5
101150074155 DHFR gene Proteins 0.000 description 5
241000282412 Homo Species 0.000 description 5
239000012980 RPMI-1640 medium Substances 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
239000000654 additive Substances 0.000 description 5
230000007815 allergy Effects 0.000 description 5
102000012086 alpha-L-Fucosidase Human genes 0.000 description 5
108010061314 alpha-L-Fucosidase Proteins 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
238000010364 biochemical engineering Methods 0.000 description 5
239000001506 calcium phosphate Substances 0.000 description 5
229910000389 calcium phosphate Inorganic materials 0.000 description 5
235000011010 calcium phosphates Nutrition 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
239000001913 cellulose Substances 0.000 description 5
229920002678 cellulose Polymers 0.000 description 5
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 5
238000013461 design Methods 0.000 description 5
238000002523 gelfiltration Methods 0.000 description 5
239000008103 glucose Substances 0.000 description 5
230000016784 immunoglobulin production Effects 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000001638 lipofection Methods 0.000 description 5
238000005259 measurement Methods 0.000 description 5
238000000691 measurement method Methods 0.000 description 5
238000002703 mutagenesis Methods 0.000 description 5
235000016709 nutrition Nutrition 0.000 description 5
230000035764 nutrition Effects 0.000 description 5
239000002245 particle Substances 0.000 description 5
238000011002 quantification Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000008107 starch Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
239000013589 supplement Substances 0.000 description 5
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
208000035143 Bacterial infection Diseases 0.000 description 4
241000283707 Capra Species 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
241000701489 Cauliflower mosaic virus Species 0.000 description 4
108020004635 Complementary DNA Proteins 0.000 description 4
108010021472 Fc gamma receptor IIB Proteins 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
240000007594 Oryza sativa Species 0.000 description 4
235000007164 Oryza sativa Nutrition 0.000 description 4
240000004713 Pisum sativum Species 0.000 description 4
235000019764 Soybean Meal Nutrition 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
229910021529 ammonia Inorganic materials 0.000 description 4
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
229910052921 ammonium sulfate Inorganic materials 0.000 description 4
235000011130 ammonium sulphate Nutrition 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
208000022362 bacterial infectious disease Diseases 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000010805 cDNA synthesis kit Methods 0.000 description 4
229910000019 calcium carbonate Inorganic materials 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
239000006143 cell culture medium Substances 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
238000000354 decomposition reaction Methods 0.000 description 4
210000004443 dendritic cell Anatomy 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
238000010828 elution Methods 0.000 description 4
210000003979 eosinophil Anatomy 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
229930027917 kanamycin Natural products 0.000 description 4
229960000318 kanamycin Drugs 0.000 description 4
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
229930182823 kanamycin A Natural products 0.000 description 4
238000010841 mRNA extraction Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
235000005985 organic acids Nutrition 0.000 description 4
230000037361 pathway Effects 0.000 description 4
239000013600 plasmid vector Substances 0.000 description 4
LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
238000003127 radioimmunoassay Methods 0.000 description 4
238000005215 recombination Methods 0.000 description 4
235000009566 rice Nutrition 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000004455 soybean meal Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
150000008163 sugars Chemical class 0.000 description 4
230000008685 targeting Effects 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
MVMSCBBUIHUTGJ-UHFFFAOYSA-N 10108-97-1 Natural products C1=2NC(N)=NC(=O)C=2N=CN1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OC1OC(CO)C(O)C(O)C1O MVMSCBBUIHUTGJ-UHFFFAOYSA-N 0.000 description 3
101150033839 4 gene Proteins 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
241001203868 Autographa californica Species 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 3
229930192334 Auxin Natural products 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
241000699800 Cricetinae Species 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
229930091371 Fructose Natural products 0.000 description 3
239000005715 Fructose Substances 0.000 description 3
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
MVMSCBBUIHUTGJ-GDJBGNAASA-N GDP-alpha-D-mannose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=C(NC(=O)C=2N=C1)N)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O MVMSCBBUIHUTGJ-GDJBGNAASA-N 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
101150003028 Hprt1 gene Proteins 0.000 description 3
206010020649 Hyperkeratosis Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
240000004322 Lens culinaris Species 0.000 description 3
102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 3
235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
241001494479 Pecora Species 0.000 description 3
235000010582 Pisum sativum Nutrition 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
240000003768 Solanum lycopersicum Species 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
108091023045 Untranslated Region Proteins 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
239000000074 antisense oligonucleotide Substances 0.000 description 3
238000012230 antisense oligonucleotides Methods 0.000 description 3
239000002363 auxin Substances 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
238000010804 cDNA synthesis Methods 0.000 description 3
239000002775 capsule Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
NFLRWRCXIJABMY-UHFFFAOYSA-M cesium diaminomethylideneazanium 2,2,2-trifluoroacetate thiocyanate Chemical compound [Cs+].[S-]C#N.NC(N)=N.OC(=O)C(F)(F)F NFLRWRCXIJABMY-UHFFFAOYSA-M 0.000 description 3
235000013330 chicken meat Nutrition 0.000 description 3
238000012136 culture method Methods 0.000 description 3
238000005520 cutting process Methods 0.000 description 3
UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 3
239000004062 cytokinin Substances 0.000 description 3
238000003113 dilution method Methods 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
229940126864 fibroblast growth factor Drugs 0.000 description 3
239000007850 fluorescent dye Substances 0.000 description 3
229930182830 galactose Natural products 0.000 description 3
230000002414 glycolytic effect Effects 0.000 description 3
150000002337 glycosamines Chemical class 0.000 description 3
239000008187 granular material Substances 0.000 description 3
CBCIHIVRDWLAME-UHFFFAOYSA-N hexanitrodiphenylamine Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O CBCIHIVRDWLAME-UHFFFAOYSA-N 0.000 description 3
210000003630 histaminocyte Anatomy 0.000 description 3
SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
108091008042 inhibitory receptors Proteins 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
210000001821 langerhans cell Anatomy 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
230000013011 mating Effects 0.000 description 3
235000013336 milk Nutrition 0.000 description 3
239000008267 milk Substances 0.000 description 3
210000004080 milk Anatomy 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
230000002265 prevention Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000004007 reversed phase HPLC Methods 0.000 description 3
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
238000002741 site-directed mutagenesis Methods 0.000 description 3
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
238000011830 transgenic mouse model Methods 0.000 description 3
238000013519 translation Methods 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
SXOUIMVOMIGLHO-AATRIKPKSA-N (E)-3-(indol-2-yl)acrylic acid Chemical compound C1=CC=C2NC(/C=C/C(=O)O)=CC2=C1 SXOUIMVOMIGLHO-AATRIKPKSA-N 0.000 description 2
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
101710197633 Actin-1 Proteins 0.000 description 2
241000589158 Agrobacterium Species 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
239000004254 Ammonium phosphate Substances 0.000 description 2
FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 2
229920001342 Bakelite® Polymers 0.000 description 2
101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
235000002767 Daucus carota Nutrition 0.000 description 2
244000000626 Daucus carota Species 0.000 description 2
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
241000283086 Equidae Species 0.000 description 2
241001131785 Escherichia coli HB101 Species 0.000 description 2
241001646716 Escherichia coli K-12 Species 0.000 description 2
108010008165 Etanercept Proteins 0.000 description 2
108010073757 Evonymous europa lectin Proteins 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
102000001690 Factor VIII Human genes 0.000 description 2
108010054218 Factor VIII Proteins 0.000 description 2
108010045674 Fucose-1-phosphate guanylyltransferase Proteins 0.000 description 2
101150094690 GAL1 gene Proteins 0.000 description 2
102100021736 Galectin-1 Human genes 0.000 description 2
102100024637 Galectin-10 Human genes 0.000 description 2
101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 2
101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
102000009465 Growth Factor Receptors Human genes 0.000 description 2
108010009202 Growth Factor Receptors Proteins 0.000 description 2
206010018910 Haemolysis Diseases 0.000 description 2
102000002812 Heat-Shock Proteins Human genes 0.000 description 2
108010004889 Heat-Shock Proteins Proteins 0.000 description 2
108010058611 Helix lectin Proteins 0.000 description 2
240000005979 Hordeum vulgare Species 0.000 description 2
235000007340 Hordeum vulgare Nutrition 0.000 description 2
241000243251 Hydra Species 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
101150102264 IE gene Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
102000016844 Immunoglobulin-like domains Human genes 0.000 description 2
108050006430 Immunoglobulin-like domains Proteins 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
241000235649 Kluyveromyces Species 0.000 description 2
241001138401 Kluyveromyces lactis Species 0.000 description 2
102000008192 Lactoglobulins Human genes 0.000 description 2
108010060630 Lactoglobulins Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
235000010666 Lens esculenta Nutrition 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
240000004658 Medicago sativa Species 0.000 description 2
235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
102000003792 Metallothionein Human genes 0.000 description 2
108090000157 Metallothionein Proteins 0.000 description 2
241000713869 Moloney murine leukemia virus Species 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
235000002637 Nicotiana tabacum Nutrition 0.000 description 2
244000061176 Nicotiana tabacum Species 0.000 description 2
101150012394 PHO5 gene Proteins 0.000 description 2
108010046016 Peanut Agglutinin Proteins 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
239000001888 Peptone Chemical class 0.000 description 2
108010080698 Peptones Chemical class 0.000 description 2
244000046052 Phaseolus vulgaris Species 0.000 description 2
108010009736 Protein Hydrolysates Proteins 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
108010017507 Ricinus communis agglutinin-1 Proteins 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 2
241000235070 Saccharomyces Species 0.000 description 2
241000235346 Schizosaccharomyces Species 0.000 description 2
241000235347 Schizosaccharomyces pombe Species 0.000 description 2
241000311088 Schwanniomyces Species 0.000 description 2
235000002595 Solanum tuberosum Nutrition 0.000 description 2
244000061456 Solanum tuberosum Species 0.000 description 2
241000256251 Spodoptera frugiperda Species 0.000 description 2
241000282887 Suidae Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
241001634922 Tausonia pullulans Species 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
108010022394 Threonine synthase Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
241000723873 Tobacco mosaic virus Species 0.000 description 2
108010020764 Transposases Proteins 0.000 description 2
102000008579 Transposases Human genes 0.000 description 2
241000223230 Trichosporon Species 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
235000021307 Triticum Nutrition 0.000 description 2
244000098338 Triticum aestivum Species 0.000 description 2
206010054094 Tumour necrosis Diseases 0.000 description 2
101100068489 Vicia faba AGPC gene Proteins 0.000 description 2
239000005862 Whey Substances 0.000 description 2
102000007544 Whey Proteins Human genes 0.000 description 2
108010046377 Whey Proteins Proteins 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
AJTUNRJTNFESSC-DPBDWXOKSA-N [(3s)-1-[[(2s,3r,4r,5s,6r)-6-[[(2r,3r,4r,5s,6r)-3-[[(3s)-3-dodecanoyloxytetradecanoyl]amino]-6-(hydroxymethyl)-5-phosphonooxy-4-[(3s)-3-tetradecanoyloxytetradecanoyl]oxyoxan-2-yl]oxymethyl]-2,5-dihydroxy-4-[(3s)-3-hydroxytetradecanoyl]oxyoxan-3-yl]amino]- Chemical compound O[C@H]1[C@H](OC(=O)C[C@@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)O[C@@H]1CO[C@H]1[C@H](NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@H](OP(O)(O)=O)[C@@H](CO)O1 AJTUNRJTNFESSC-DPBDWXOKSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
238000005273 aeration Methods 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
230000004520 agglutination Effects 0.000 description 2
239000012670 alkaline solution Substances 0.000 description 2
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
229910000148 ammonium phosphate Inorganic materials 0.000 description 2
235000019289 ammonium phosphates Nutrition 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
238000005571 anion exchange chromatography Methods 0.000 description 2
230000000702 anti-platelet effect Effects 0.000 description 2
230000002137 anti-vascular effect Effects 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
238000002306 biochemical method Methods 0.000 description 2
238000009395 breeding Methods 0.000 description 2
230000001488 breeding effect Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
238000005277 cation exchange chromatography Methods 0.000 description 2
230000011712 cell development Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000011098 chromatofocusing Methods 0.000 description 2
239000013611 chromosomal DNA Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
239000013599 cloning vector Substances 0.000 description 2
238000004891 communication Methods 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
229910000365 copper sulfate Inorganic materials 0.000 description 2
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
235000005822 corn Nutrition 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
239000003398 denaturant Substances 0.000 description 2
238000011033 desalting Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000007865 diluting Methods 0.000 description 2
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
235000019797 dipotassium phosphate Nutrition 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
108010039433 dolichos biflorus agglutinin Proteins 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
108010053791 erythrina lectin Proteins 0.000 description 2
230000005284 excitation Effects 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000011790 ferrous sulphate Substances 0.000 description 2
235000003891 ferrous sulphate Nutrition 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
108010015750 fucose-binding lectin Proteins 0.000 description 2
229960002518 gentamicin Drugs 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
239000006451 grace's insect medium Substances 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
150000002402 hexoses Chemical class 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000012744 immunostaining Methods 0.000 description 2
PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229940028885 interleukin-4 Drugs 0.000 description 2
229940100602 interleukin-5 Drugs 0.000 description 2
229940100601 interleukin-6 Drugs 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
238000001155 isoelectric focusing Methods 0.000 description 2
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
238000000111 isothermal titration calorimetry Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
108010003491 maclurin Proteins 0.000 description 2
GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
239000004137 magnesium phosphate Substances 0.000 description 2
229910000157 magnesium phosphate Inorganic materials 0.000 description 2
229960002261 magnesium phosphate Drugs 0.000 description 2
235000010994 magnesium phosphates Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
210000004216 mammary stem cell Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
235000013372 meat Nutrition 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
235000013379 molasses Nutrition 0.000 description 2
239000002808 molecular sieve Substances 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
235000019796 monopotassium phosphate Nutrition 0.000 description 2
239000003471 mutagenic agent Substances 0.000 description 2
231100000707 mutagenic chemical Toxicity 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical class [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
235000019319 peptone Nutrition 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
150000008300 phosphoramidites Chemical class 0.000 description 2
239000003375 plant hormone Substances 0.000 description 2
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
238000001742 protein purification Methods 0.000 description 2
239000008213 purified water Substances 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
230000005855 radiation Effects 0.000 description 2
239000012857 radioactive material Substances 0.000 description 2
238000001223 reverse osmosis Methods 0.000 description 2
238000004366 reverse phase liquid chromatography Methods 0.000 description 2
238000005185 salting out Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
230000035939 shock Effects 0.000 description 2
108010076805 snowdrop lectin Proteins 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
238000000638 solvent extraction Methods 0.000 description 2
210000001082 somatic cell Anatomy 0.000 description 2
108010002645 sophora japonica agglutinin Proteins 0.000 description 2
108010048090 soybean lectin Proteins 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
238000001262 western blot Methods 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
235000021249 α-casein Nutrition 0.000 description 2
235000021247 β-casein Nutrition 0.000 description 2
UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical group OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 1
SESQMDHICVIJCF-PCMWHEESSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1 Chemical compound C([C@@H](C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 SESQMDHICVIJCF-PCMWHEESSA-N 0.000 description 1
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
FVPXJPVSJNSJBL-UHFFFAOYSA-N 1h-pyrimidine-2,4-dione;1,3-thiazole Chemical class C1=CSC=N1.O=C1C=CNC(=O)N1 FVPXJPVSJNSJBL-UHFFFAOYSA-N 0.000 description 1
DOLVFFGLNYMIPV-UHFFFAOYSA-N 2,4-ditert-butyl-6-[3-[(3,5-ditert-butyl-2-hydroxyphenyl)methylideneamino]propyliminomethyl]phenol Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(C=NCCCN=CC=2C(=C(C=C(C=2)C(C)(C)C)C(C)(C)C)O)=C1O DOLVFFGLNYMIPV-UHFFFAOYSA-N 0.000 description 1
WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 1
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
101150044182 8 gene Proteins 0.000 description 1
241000221688 Aleuria aurantia Species 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
241000220487 Bauhinia Species 0.000 description 1
FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
244000045232 Canavalia ensiformis Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
102100024746 Dihydrofolate reductase Human genes 0.000 description 1
108010041308 Endothelial Growth Factors Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
RJZVPALIPMSJIO-UHFFFAOYSA-M FC(C(=O)O)(F)F.C(C)(=O)O.[Cs+].[S-]C#N.NC(=N)N Chemical compound FC(C(=O)O)(F)F.C(C)(=O)O.[Cs+].[S-]C#N.NC(=N)N RJZVPALIPMSJIO-UHFFFAOYSA-M 0.000 description 1
108091008794 FGF receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
235000016623 Fragaria vesca Nutrition 0.000 description 1
240000009088 Fragaria x ananassa Species 0.000 description 1
235000011363 Fragaria x ananassa Nutrition 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
241000219726 Griffonia simplicifolia Species 0.000 description 1
241000234473 Hippeastrum Species 0.000 description 1
101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102000009490 IgG Receptors Human genes 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
241000219739 Lens Species 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 1
241001521394 Maackia amurensis Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
FUSGACRLAFQQRL-UHFFFAOYSA-N N-Ethyl-N-nitrosourea Chemical compound CCN(N=O)C(N)=O FUSGACRLAFQQRL-UHFFFAOYSA-N 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
241001532689 Narcissus pseudonarcissus Species 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108700020797 Parathyroid Hormone-Related Proteins 0.000 description 1
102000043299 Parathyroid hormone-related Human genes 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
241000219843 Pisum Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
235000010580 Psophocarpus tetragonolobus Nutrition 0.000 description 1
244000046095 Psophocarpus tetragonolobus Species 0.000 description 1
240000000528 Ricinus communis Species 0.000 description 1
235000018735 Sambucus canadensis Nutrition 0.000 description 1
244000151637 Sambucus canadensis Species 0.000 description 1
241000207763 Solanum Species 0.000 description 1
235000002634 Solanum Nutrition 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
240000002657 Thymus vulgaris Species 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
241000255985 Trichoplusia Species 0.000 description 1
235000018907 Tylosema fassoglense Nutrition 0.000 description 1
241000219873 Vicia Species 0.000 description 1
241000219995 Wisteria Species 0.000 description 1
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000999 acridine dye Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
238000007792 addition Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
229940125644 antibody drug Drugs 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
239000004637 bakelite Substances 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
230000029803 blastocyst development Effects 0.000 description 1
239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
235000007123 blue elder Nutrition 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
235000001046 cacaotero Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000005515 coenzyme Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
108020001096 dihydrofolate reductase Proteins 0.000 description 1
239000000539 dimer Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
235000007124 elderberry Nutrition 0.000 description 1
239000003480 eluent Substances 0.000 description 1
229940073621 enbrel Drugs 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
108010014507 erythroagglutinating phytohemagglutinin Proteins 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960000403 etanercept Drugs 0.000 description 1
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
235000008995 european elder Nutrition 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
238000003234 fluorescent labeling method Methods 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
231100000221 frame shift mutation induction Toxicity 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960001008 heparin sodium Drugs 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
102000054751 human RUNX1T1 Human genes 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001948 isotopic labelling Methods 0.000 description 1
108010084553 jacalin Proteins 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000012737 microarray-based gene expression Methods 0.000 description 1
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
238000012243 multiplex automated genomic engineering Methods 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000005180 public health Effects 0.000 description 1
239000000941 radioactive substance Substances 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229940035722 triiodothyronine Drugs 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000001177 vas deferen Anatomy 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

JP2003582297A 2002-04-09 2003-04-09 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法 Pending JPWO2003085119A1 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2002106950		2002-04-09
JP2002106950		2002-04-09
PCT/JP2003/004504 WO2003085119A1 (fr)	2002-04-09	2003-04-09	Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia

Publications (1)

Publication Number	Publication Date
JPWO2003085119A1 true JPWO2003085119A1 (ja)	2005-08-11

Family

ID=28786448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2003582297A Pending JPWO2003085119A1 (ja)	2002-04-09	2003-04-09	抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法

Country Status (6)

Country	Link
US (2)	US20040259150A1 (fr)
EP (1)	EP1498491A4 (fr)
JP (1)	JPWO2003085119A1 (fr)
AU (1)	AU2003236018A1 (fr)
CA (1)	CA2481658A1 (fr)
WO (1)	WO2003085119A1 (fr)

Families Citing this family (642)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
EP2275540B1 (fr)	1999-04-09	2016-03-23	Kyowa Hakko Kirin Co., Ltd.	Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
FR2807767B1 (fr)	2000-04-12	2005-01-14	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-d
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US7662925B2 (en)	2002-03-01	2010-02-16	Xencor, Inc.	Optimized Fc variants and methods for their generation
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US8188231B2 (en)	2002-09-27	2012-05-29	Xencor, Inc.	Optimized FC variants
US7691568B2 (en)	2002-04-09	2010-04-06	Kyowa Hakko Kirin Co., Ltd	Antibody composition-containing medicament
US8388955B2 (en)	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
US8084582B2 (en)	2003-03-03	2011-12-27	Xencor, Inc.	Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en)	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en)	2003-05-02	2015-06-09	Xencor, Inc.	Optimized Fc variants
US8101720B2 (en)	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
JPWO2005053742A1 (ja) *	2003-12-04	2007-06-28	協和醗酵工業株式会社	抗体組成物を含有する医薬
EP2053062A1 (fr)	2004-03-24	2009-04-29	Xencor, Inc.	Variantes d'immunoglobine en dehors de la région Fc
AR049292A1 (es) *	2004-06-04	2006-07-12	Genentech Inc	Metodo para tratar lupus con un anticuerpo cd20
US20060051345A1 (en) *	2004-06-04	2006-03-09	Genentech, Inc.	Method for treating multiple sclerosis
ATE486610T1 (de)	2004-07-09	2010-11-15	Chugai Pharmaceutical Co Ltd	Anti-glypican-3-antikörper
US20150010550A1 (en)	2004-07-15	2015-01-08	Xencor, Inc.	OPTIMIZED Fc VARIANTS
EP1800693B1 (fr)	2004-08-24	2013-07-17	Chugai Seiyaku Kabushiki Kaisha	Therapie adjuvante utilisant des anticorps anti-glypicane 3
WO2006041680A2 (fr)	2004-10-05	2006-04-20	Genentech, Inc.	Methode de traitement de l'angeite
TWI468514B (zh)	2004-10-26	2015-01-11	Chugai Pharmaceutical Co Ltd	Sugar chain modified phosphatidylinositol glyphosyl 3 antibody
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
US8367805B2 (en)	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
CN102746404B (zh)	2004-11-12	2016-01-20	赞科股份有限公司	对FcRn的结合被改变的Fc变体
US8802820B2 (en)	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
NZ556286A (en)	2005-02-07	2010-11-26	Glycart Biotechnology Ag	Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
ES2530265T3 (es)	2005-07-21	2015-02-27	Genmab A/S	Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
EP1931709B1 (fr)	2005-10-03	2016-12-07	Xencor, Inc.	Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées
CA2625998C (fr)	2005-10-06	2015-12-01	Xencor, Inc.	Anticorps anti-cd30 optimises
US20070087005A1 (en)	2005-10-14	2007-04-19	Lazar Gregory A	Anti-glypican-3 antibody
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
CN105859886A (zh)	2005-12-02	2016-08-17	健泰科生物技术公司	牵涉与il-22和il-22r结合的抗体的组合物和方法
AR058568A1 (es)	2005-12-20	2008-02-13	Bristol Myers Squibb Co	Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PL2253644T3 (pl) *	2005-12-20	2014-04-30	Bristol Myers Squibb Co	Kompozycje i sposoby wytwarzania kompozycji
RU2450020C2 (ru)	2006-01-05	2012-05-10	Дженентек, Инк.	АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR20080094064A (ko)	2006-01-17	2008-10-22	바이오렉스 쎄라퓨틱스, 인코포레이티드	식물에서 ｎ-글리칸의 인간화 및 최적화 조성물 및 방법
US20090060921A1 (en) *	2006-01-17	2009-03-05	Biolex Therapeutics, Inc.	Glycan-optimized anti-cd20 antibodies
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
AR060978A1 (es)	2006-05-30	2008-07-23	Genentech Inc	Anticuerpos e inmunoconjugados y sus usos
AU2007319672B2 (en) *	2006-06-06	2011-06-30	Genentech, Inc.	Anti-DLL4 antibodies and methods using same
CA2654304A1 (fr) *	2006-06-06	2007-12-13	Genentech, Inc.	Compositions et procedes destines a moduler le developpement vasculaire
CN101622276B (zh)	2006-07-18	2015-04-22	赛诺菲-安万特	用于治疗癌症的抗epha2的拮抗抗体
ES2612383T3 (es)	2006-07-19	2017-05-16	The Trustees Of The University Of Pennsylvania	WSX-1/IL-27 como una diana para respuestas antiinflamatorias
AR062223A1 (es)	2006-08-09	2008-10-22	Glycart Biotechnology Ag	Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
DK2383297T5 (da)	2006-08-14	2022-07-04	Xencor Inc	Optimerede antistoffer rettet mod CD19
US20100297103A1 (en)	2006-09-14	2010-11-25	Medical & Biological Laboratories Co., Ltd.	Antibody having enhanced adcc activity and method for production thereof
WO2008036688A2 (fr)	2006-09-18	2008-03-27	Xencor, Inc.	Anticorps optimisés ciblant l'antigène hm1.24
MX2009003774A (es)	2006-10-12	2009-04-22	Genentech Inc	Anticuerpos para linfotoxina-alfa.
EP1914242A1 (fr)	2006-10-19	2008-04-23	Sanofi-Aventis	Nouveau anticorps Anti-CD38 pour le traitement du cancer
SI2502938T1 (sl)	2006-10-27	2015-05-29	Genentech, Inc.	Protitelesa in imunokonjugati in njihove uporabe
CL2007003411A1 (es) *	2006-11-28	2008-07-04	Centelion	Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
CA2676766A1 (fr)	2007-02-09	2008-08-21	Genentech, Inc.	Anticorps anti-robo4 et utilisations de ceux-ci
RU2479629C2 (ru) *	2007-03-07	2013-04-20	Гликофи, Инк.	Продукция гликопротеинов с модифицированным фукозилированием
RU2549701C2 (ru)	2007-05-07	2015-04-27	Медиммун, Ллк	Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний
EP2068927B1 (fr)	2007-05-14	2015-10-21	MedImmune, LLC	Methodes de reduction de niveaux d'eosinophiles
EP2169404B1 (fr) *	2007-06-18	2016-01-27	Chugai Seiyaku Kabushiki Kaisha	PROCÉDÉ DE MESURE DE L'ACTIVITÉ DE LIAISON D'UN ANTICORPS AVEC UN ANTIGÈNE ET AVEC UN RÉCEPTEUR Fc
CL2008002886A1 (es)	2007-09-26	2009-12-04	Chugai Pharmaceutical Co Ltd	Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
SI2514436T1 (en)	2007-11-07	2018-04-30	Genentech, Inc.	IL-22 for use in the treatment of microbial diseases
AR069501A1 (es)	2007-11-30	2010-01-27	Genentech Inc	Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
SI2808343T1 (sl)	2007-12-26	2019-10-30	Xencor Inc	Fc-variante s spremenjeno vezavo na FcRn
TW201014605A (en) *	2008-09-16	2010-04-16	Genentech Inc	Methods for treating progressive multiple sclerosis
KR20190025057A (ko)	2008-10-14	2019-03-08	제넨테크, 인크.	이뮤노글로불린 변이체 및 그의 용도
WO2010075249A2 (fr)	2008-12-22	2010-07-01	Genentech, Inc.	Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
MX2011006870A (es)	2008-12-23	2011-07-19	Genentech Inc	Variantes de inmunoglobulina con union alterada a proteina a.
ES2572728T3 (es)	2009-03-20	2016-06-02	F. Hoffmann-La Roche Ag	Anticuerpos anti-HER biespecíficos
CA2754163C (fr)	2009-03-25	2019-04-09	Genentech, Inc.	Anticorps anti-fgfr3 et procedes d'utilisation de ceux-ci
NZ594343A (en)	2009-03-25	2013-10-25	Genentech Inc	Novel anti-alpha5beta1 antibodies and uses thereof
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
US20100316639A1 (en)	2009-06-16	2010-12-16	Genentech, Inc.	Biomarkers for igf-1r inhibitor therapy
TW201106972A (en)	2009-07-27	2011-03-01	Genentech Inc	Combination treatments
NZ597531A (en)	2009-07-31	2014-05-30	Genentech Inc	Inhibition of tumor metastasis using bv8- or g-csf-antagonists
BR112012003983A2 (pt)	2009-08-31	2021-09-14	Roche Glycart Ag	Molecula de ligação abm moleculas de ligação de antigenos abm variante polipeptideo isolado molecula de ligação de antigeneos humanizada anticorpo polinucleotideo isolado composição vetor celula hospedeira metodo de produção de abm metodo de indução da lise celular de tumor, metodo de diagnostico de doença em pacientes que possuem um cancer metodo de aumento de tempo de sobrevivencia em pacientes que possuem um cancer metodo de indução em pacientes de regressão de um motor uso abm e invenção
US9321823B2 (en)	2009-09-02	2016-04-26	Genentech, Inc.	Mutant smoothened and methods of using the same
US9493578B2 (en)	2009-09-02	2016-11-15	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AR078470A1 (es)	2009-10-02	2011-11-09	Sanofi Aventis	Anticuerpos que se unen especificamente al receptor epha2
NZ599337A (en)	2009-10-22	2013-05-31	Genentech Inc	Anti-hepsin antibodies and methods using same
WO2011056497A1 (fr)	2009-10-26	2011-05-12	Genentech, Inc.	Compositions de récepteur de l'activine de type iib et leurs méthodes d'utilisation
WO2011056502A1 (fr)	2009-10-26	2011-05-12	Genentech, Inc.	Compositions du gene recepteur de proteine morphogenetique osseuse type ii et procedes d'utilisation
WO2011056494A1 (fr)	2009-10-26	2011-05-12	Genentech, Inc.	Combinaisons d'antagonistes de la kinase-1 du type récepteur de l'activine et d'antagonistes vegfr3
AU2010315101B2 (en)	2009-11-04	2016-01-28	Fabrus Llc	Methods for affinity maturation-based antibody optimization
RU2585488C2 (ru)	2009-11-05	2016-05-27	Дженентек, Инк.	Способы и композиция для секреции гетерологичных полипептидов
TWI505836B (zh)	2009-12-11	2015-11-01	Genentech Inc	抗－ｖｅｇｆ－ｃ抗體及其使用方法
SI2516465T1 (sl)	2009-12-23	2016-08-31	F. Hoffmann-La Roche Ag	Protelesa proti bv8 in uporaba le-teh
US8362210B2 (en)	2010-01-19	2013-01-29	Xencor, Inc.	Antibody variants with enhanced complement activity
CN102933231B (zh)	2010-02-10	2015-07-29	伊缪诺金公司	Cd20抗体及其用途
WO2011101328A2 (fr)	2010-02-18	2011-08-25	Roche Glycart Ag	Traitement au moyen d'un anticorps anti-egfr de la classe igg humanisé et d'un anticorps contre le récepteur du facteur de croissance 1 analogue à l'insuline
JP5981853B2 (ja)	2010-02-18	2016-08-31	ジェネンテック，インコーポレイテッド	ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
AU2011222012C1 (en)	2010-03-02	2015-02-26	Kyowa Kirin Co., Ltd.	Modified antibody composition
NZ602040A (en)	2010-03-24	2014-12-24	Genentech Inc	Anti-lrp6 antibodies
WO2011147834A1 (fr)	2010-05-26	2011-12-01	Roche Glycart Ag	Anticorps contre cd19 et utilisations associées
BR112012029866A2 (pt)	2010-06-03	2017-03-07	Genentech Inc	método para a determinação da presença de uma proteína steap-1
RU2577986C2 (ru)	2010-06-18	2016-03-20	Дженентек, Инк.	Антитела против axl и способы их применения
WO2011161119A1 (fr)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Anticorps contre le récepteur du facteur de croissance insulinique i et ses utilisations
WO2011161189A1 (fr)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anticorps anti-hepsine et leurs procédés d'utilisation
NZ605449A (en)	2010-07-09	2015-03-27	Genentech Inc	Anti-neuropilin antibodies and methods of use
WO2012010582A1 (fr)	2010-07-21	2012-01-26	Roche Glycart Ag	Anticorps anti-cxcr5 et leurs méthodes d'utilisation
CN103153341B (zh)	2010-08-03	2015-05-27	霍夫曼-拉罗奇有限公司	慢性淋巴细胞性白血病(cll)生物标志物
CA2805564A1 (fr)	2010-08-05	2012-02-09	Stefan Jenewein	Proteine de fusion anticorps anti-cmh cytokine antivirale
BR112013002444A2 (pt)	2010-08-13	2016-05-24	Roche Glycart Ag	anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
SG187746A1 (en)	2010-08-13	2013-03-28	Roche Glycart Ag	Anti-fap antibodies and methods of use
CA2805054A1 (fr)	2010-08-25	2012-03-01	F. Hoffmann-La Roche Ag	Anticorps contre il-18r1 et leurs utilisations
SG10201408229WA (en)	2010-08-31	2015-02-27	Genentech Inc	Biomarkers and methods of treatment
WO2012047968A2 (fr)	2010-10-05	2012-04-12	Genentech, Inc.	Mutant smoothened et ses procédés d'utilisation
WO2012064836A1 (fr)	2010-11-10	2012-05-18	Genentech, Inc.	Méthodes et compositions pour l'immunothérapie de maladies neurales
AU2011343570B2 (en)	2010-12-16	2016-11-03	Genentech, Inc.	Diagnosis and treatments relating to TH2 inhibition
MX345519B (es)	2010-12-20	2017-02-01	Genentech Inc	Anticuerpos anti-mesotelina e inmunoconjugados.
MA34818B1 (fr)	2010-12-22	2014-01-02	Genentech Inc	Anticorps anti-pcsk9 et procédés d'utilisation
WO2012092539A2 (fr)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Anticorps contre dll4 et leurs utilisations
CA2824252A1 (fr)	2011-02-10	2012-08-16	Roche Glycart Ag	Immunotherapie amelioree
CN103403025B (zh)	2011-02-28	2016-10-12	弗·哈夫曼-拉罗切有限公司	单价抗原结合蛋白
ES2549638T3 (es)	2011-02-28	2015-10-30	F. Hoffmann-La Roche Ag	Proteínas de unión a antígeno
NZ614125A (en)	2011-03-02	2015-07-31	Roche Glycart Ag	Cea antibodies
PT2691417T (pt)	2011-03-29	2018-10-31	Roche Glycart Ag	Variantes de fc de anticorpos
JP2014516511A (ja)	2011-04-07	2014-07-17	ジェネンテック，インコーポレイテッド	抗ｆｇｆｒ４抗体及び使用方法
WO2012146630A1 (fr)	2011-04-29	2012-11-01	F. Hoffmann-La Roche Ag	Polypeptides acylés en position n-terminale, leurs procédés de préparation et leurs utilisations
EA201892619A1 (ru)	2011-04-29	2019-04-30	Роше Гликарт Аг	Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP5987053B2 (ja)	2011-05-12	2016-09-06	ジェネンテック，インコーポレイテッド	フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングｌｃ−ｍｓ／ｍｓ法
WO2012158704A1 (fr)	2011-05-16	2012-11-22	Genentech, Inc.	Agonistes de fgfr1 et leurs procédés d'utilisation
AR086924A1 (es)	2011-06-15	2014-01-29	Hoffmann La Roche	Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion
SG195077A1 (en)	2011-06-22	2013-12-30	Hoffmann La Roche	Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
WO2013003680A1 (fr)	2011-06-30	2013-01-03	Genentech, Inc.	Formulations d'anticorps anti-c-met
MX2014001766A (es)	2011-08-17	2014-05-01	Genentech Inc	Anticuerpos de neuregulina y sus usos.
CN103890008A (zh)	2011-08-17	2014-06-25	霍夫曼-拉罗奇有限公司	在顽固性肿瘤中抑制血管发生
SI2748202T1 (sl)	2011-08-23	2018-10-30	Roche Glycart Ag	Bispecifične molekule, ki se vežejo na antigen
US9309306B2 (en)	2011-08-23	2016-04-12	Roche Glycart Ag	Anti-MCSP antibodies
KR20140068062A (ko)	2011-09-15	2014-06-05	제넨테크, 인크.	분화의 촉진 방법
MX2014002990A (es)	2011-09-19	2014-05-21	Genentech Inc	Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
US9663573B2 (en)	2011-10-05	2017-05-30	Genentech, Inc.	Methods of treating liver conditions using Notch2 antagonists
KR102102862B1 (ko)	2011-10-14	2020-04-22	제넨테크, 인크.	항-HtrA1 항체 및 사용 방법
KR20140084164A (ko)	2011-10-15	2014-07-04	제넨테크, 인크.	암의 치료를 위한 scd1 길항제
WO2013059531A1 (fr)	2011-10-20	2013-04-25	Genentech, Inc.	Anticorps anti-gcgr et leurs utilisations
AU2012328980A1 (en)	2011-10-28	2014-04-24	Genentech, Inc.	Therapeutic combinations and methods of treating melanoma
BR112014012005A2 (pt)	2011-11-21	2017-12-19	Genentech Inc	composições, métodos, formulação farmacêutica e artigo
EP2788024A1 (fr)	2011-12-06	2014-10-15	F.Hoffmann-La Roche Ag	Formulation d'anticorps
PL2794651T3 (pl)	2011-12-22	2022-12-27	F.Hoffmann-La Roche Ag	Kombinacje elementów wektora ekspresyjnego, nowe sposoby generowania komórek produkcyjnych i ich zastosowanie do rekombinowanej produkcji polipeptydów
KR20140107295A (ko)	2011-12-22	2014-09-04	에프. 호프만-라 로슈 아게	진핵 세포용 전장 항체 표시 시스템 및 그것의 용도
KR102280111B1 (ko)	2011-12-22	2021-07-21	에프. 호프만-라 로슈 아게	발현 벡터 구성, 신규한 생산 세포 생성 방법 및 폴리펩티드의 재조합 생산을 위한 그의 용도
AR089434A1 (es)	2011-12-23	2014-08-20	Genentech Inc	Procedimiento para preparar formulaciones con alta concentracion de proteinas
WO2013101771A2 (fr)	2011-12-30	2013-07-04	Genentech, Inc.	Compositions et méthode pour le traitement de maladies auto-immunes
WO2013106485A2 (fr)	2012-01-09	2013-07-18	The Scripps Research Institute	Régions déterminant la complémentarité ultralongues et utilisations associées
WO2013106489A1 (fr)	2012-01-09	2013-07-18	The Scripps Research Institute	Anticorps humanisés à cdr3 ultralongues
JP6242813B2 (ja)	2012-01-18	2017-12-06	ジェネンテック，インコーポレイテッド	抗ｌｒｐ５抗体及び使用方法
CN104168920A (zh)	2012-01-18	2014-11-26	霍夫曼-拉罗奇有限公司	使用fgf19调控剂的方法
WO2013116287A1 (fr)	2012-01-31	2013-08-08	Genentech, Inc.	ANTICORPS ANTI-IgE SE LIANT À M1' ET LEURS PROCÉDÉS D'UTILISATION
BR112014019741A2 (pt)	2012-02-11	2020-12-22	Genentech, Inc	Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
JP6152120B2 (ja)	2012-02-15	2017-06-21	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｆｃ受容体に基づくアフィニティークロマトグラフィー
JP2015514710A (ja)	2012-03-27	2015-05-21	ジェネンテック，インコーポレイテッド	Ｈｅｒ３阻害剤に関する診断及び治療
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
RU2014148162A (ru)	2012-05-01	2016-06-20	Дженентек, Инк.	Анти-pmel17 антитела и их иммуноконъюгаты
WO2013170191A1 (fr)	2012-05-11	2013-11-14	Genentech, Inc.	Procédés d'utilisation d'antagonistes de biosynthèse de nicotinamide adénine dinucléotide à partir de nicotinamide
US9695454B2 (en)	2012-05-23	2017-07-04	Glykos Finland Oy	Production of fucosylated glycoproteins
WO2013177470A1 (fr)	2012-05-23	2013-11-28	Genentech, Inc.	Procédé de sélection d'agents thérapeutiques
CN104364266A (zh)	2012-06-15	2015-02-18	霍夫曼-拉罗奇有限公司	抗-pcsk9抗体,制剂,剂量给药,和使用方法
CA2872192A1 (fr)	2012-07-04	2014-01-09	F. Hoffmann-La Roche Ag	Anticorps anti-biotine et procedes d'utilisation correspondants
ES2604012T3 (es)	2012-07-04	2017-03-02	F. Hoffmann-La Roche Ag	Conjugados de antígeno-anticuerpo unidos covalentemente
MX353951B (es)	2012-07-04	2018-02-07	Hoffmann La Roche	Anticuerpos de anti-teofilina y metodos de uso.
CN110042114A (zh)	2012-07-05	2019-07-23	弗·哈夫曼-拉罗切有限公司	表达和分泌***
TW201408698A (zh)	2012-07-09	2014-03-01	Genentech Inc	抗ｃｄ７９ｂ抗體及免疫結合物
SG11201500087VA (en)	2012-07-09	2015-02-27	Genentech Inc	Immunoconjugates comprising anti-cd22 antibodies
CA2874904A1 (fr)	2012-07-09	2014-01-16	Genentech, Inc.	Immunoconjugues comprenant des anticorps anti-cd22
SG11201500096YA (en)	2012-07-09	2015-02-27	Genentech Inc	Immunoconjugates comprising anti - cd79b antibodies
HUE056217T2 (hu)	2012-07-13	2022-02-28	Roche Glycart Ag	Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
SG10201800535XA (en)	2012-08-07	2018-02-27	Roche Glycart Ag	Composition comprising two antibodies engineered to have reduced and increased effector function
JP6273205B2 (ja)	2012-10-05	2018-01-31	協和発酵キリン株式会社	ヘテロダイマータンパク質組成物
US10260089B2 (en)	2012-10-29	2019-04-16	The Research Foundation Of The State University Of New York	Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
CA2890207A1 (fr)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Nouvelles molecules de fusion de ntrk1 et leurs utilisations
CA2884431A1 (fr)	2012-11-08	2014-05-15	F. Hoffmann-La Roche Ag	Proteines de liaison a l'antigene her3 se liant a l'epingle a cheveux beta de her3
WO2014078268A2 (fr)	2012-11-13	2014-05-22	Genentech, Inc.	Anticorps anti-hémagglutinine et leurs procédés d'utilisation
JP6475167B2 (ja)	2012-12-21	2019-02-27	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質
CA3150658A1 (en)	2013-01-18	2014-07-24	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
WO2014116749A1 (fr)	2013-01-23	2014-07-31	Genentech, Inc.	Anticorps anti-vhc et méthodes d'utilisation correspondantes
JP2016509045A (ja)	2013-02-22	2016-03-24	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	がんを治療し、薬剤耐性を防止する方法
CA2896259A1 (fr)	2013-02-26	2014-09-04	Roche Glycart Ag	Anticorps anti-mcsp
US9925240B2 (en)	2013-03-06	2018-03-27	Genentech, Inc.	Methods of treating and preventing cancer drug resistance
EP2970916B1 (fr)	2013-03-13	2021-04-14	Merck Sharp & Dohme Corp.	Cellules d'insecte lépidoptère adaptées à la production de protéines recombinées
US9562099B2 (en)	2013-03-14	2017-02-07	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
WO2014159835A1 (fr)	2013-03-14	2014-10-02	Genentech, Inc.	Anticorps et immunoconjugués anti-b7-h4
CA2905070A1 (fr)	2013-03-14	2014-09-25	Genentech, Inc.	Methodes de traitement du cancer et de prevention d'une resistance a un medicament anticancereux
EP2968540A2 (fr)	2013-03-14	2016-01-20	Genentech, Inc.	Combinaisons d'un composé inhibiteur de mek avec un composé inhibiteur de her3/egfr et procédés d'utilisation
MX2015011899A (es)	2013-03-15	2016-05-05	Genentech Inc	Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
BR112015021521A2 (pt)	2013-03-15	2017-10-10	Genentech Inc	anticorpos anti-crth2 e métodos para seu uso
DK3460054T3 (da)	2013-03-15	2021-01-18	Atyr Pharma Inc	Histidyl-tRNA-syntetase-Fc-konjugater
MX2015012872A (es)	2013-03-15	2016-02-03	Ac Immune Sa	Anticuerpos anti-tau y metodos de uso.
JP6527132B2 (ja)	2013-03-15	2019-06-05	ジェネンテック，インコーポレイテッド	肝臓がんの診断及び治療のための組成物及び方法
TR201809571T4 (tr)	2013-03-15	2018-07-23	Hoffmann La Roche	Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
EP2972373B1 (fr)	2013-03-15	2019-10-09	F.Hoffmann-La Roche Ag	Biomarqueurs et méthodes de traitement d'états associés à pd-1 et pd-l1
UA118028C2 (uk)	2013-04-03	2018-11-12	Рош Глікарт Аг	Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2992012B1 (fr)	2013-04-29	2019-07-17	F.Hoffmann-La Roche Ag	Anticorps modifiés liés au récepteur fcrn humain et procédés d'utilisation
RU2687043C2 (ru)	2013-04-29	2019-05-06	Ф. Хоффманн-Ля Рош Аг	МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN105164158A (zh)	2013-04-29	2015-12-16	豪夫迈·罗氏有限公司	消除对FcRn-结合的抗-IGF-1R抗体及其在血管性眼病治疗中的用途
EP2999716A2 (fr)	2013-05-20	2016-03-30	F. Hoffmann-La Roche AG	Anticorps anti-récepteur de transferrine et procédés d'utilisation
MX369022B (es)	2013-05-31	2019-10-25	Genentech Inc	Anticuerpos anti-ácido teicoico de la pared celular y conjugados.
RU2687044C2 (ru)	2013-05-31	2019-05-06	Дженентек, Инк.	Антитела против стеночной тейхоевой кислоты и их конъюгаты
CN105814074B (zh)	2013-07-18	2020-04-21	图鲁斯生物科学有限责任公司	具有超长互补决定区的人源化抗体
EP3022224A2 (fr)	2013-07-18	2016-05-25	Fabrus, Inc.	Anticorps à régions de détermination de complémentarité ultralongues
EP4036118A1 (fr)	2013-08-01	2022-08-03	Five Prime Therapeutics, Inc.	Anticorps anti-fgfr2iiib non fucosilés
US10093978B2 (en)	2013-08-12	2018-10-09	Genentech, Inc.	Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
CN105518027A (zh)	2013-09-17	2016-04-20	豪夫迈·罗氏有限公司	使用抗lgr5抗体的方法
KR20160068855A (ko)	2013-10-11	2016-06-15	제넨테크, 인크.	Nsp4 억제제 및 사용 방법
MX2016003593A (es)	2013-10-11	2016-06-02	Hoffmann La Roche	Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
MX2016003744A (es)	2013-10-11	2016-08-11	Us Health	Anticuerpos tem8 y su uso.
MX2016004802A (es)	2013-10-18	2016-07-18	Genentech Inc	Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
RU2016119425A (ru)	2013-10-23	2017-11-28	Дженентек, Инк.	Способы диагностики и лечения эозинофильных заболеваний
AU2014351996B2 (en)	2013-11-21	2020-01-02	F. Hoffmann-La Roche Ag	Anti-alpha-synuclein antibodies and methods of use
CN113861293A (zh)	2013-12-09	2021-12-31	爱乐科斯公司	抗Siglec-8抗体及其使用方法
MA39095A1 (fr)	2013-12-13	2018-08-31	Genentech Inc	Anticorps et immunoconjugués anti-cd33
CA2934028A1 (fr)	2013-12-17	2015-06-25	Genentech, Inc.	Polytherapie comprenant des agonistes se liant a ox40 et des antagonistes se liant a l'axe pd-1
EP3083692B1 (fr)	2013-12-17	2020-02-19	F.Hoffmann-La Roche Ag	Méthode de traitement des cancers utilisant des antagonists se liant à l'axe pd-1 et des taxanes
DK3083689T3 (da)	2013-12-17	2020-08-03	Genentech Inc	Anti-CD3-antistoffer og fremgangsmåder til anvendelse
WO2015095410A1 (fr)	2013-12-17	2015-06-25	Genentech, Inc.	Méthodes de traitement du cancer à l'aide d'antagonistes se liant à l'axe pd-1 et d'anticorps anti-cd20
TWI728373B (zh)	2013-12-23	2021-05-21	美商建南德克公司	抗體及使用方法
WO2015103549A1 (fr)	2014-01-03	2015-07-09	The United States Of America, As Represented By The Secretary Department Of Health And Human Services	Anticorps neutralisants dirigés contre la env du vih-1 et leur utilisation
BR112016012666A2 (pt)	2014-01-03	2017-09-26	Hoffmann La Roche	conjugado, anticorpos, formulação farmacêutica e usos de conjugado
EP3089996B1 (fr)	2014-01-03	2021-07-28	F. Hoffmann-La Roche AG	Anticorps bispécifiques anti-récepteur des navettes de la barrière hémato-encéphalique/anti-haptène, complexes de ceux-ci et leur utilisation comme navettes de la barrière hémato-encéphalique
JP6521464B2 (ja)	2014-01-03	2019-05-29	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	共有結合で連結されたポリペプチド毒素−抗体コンジュゲート
EP3092251B1 (fr)	2014-01-06	2021-01-20	F. Hoffmann-La Roche AG	Modules navettes de barrière hémato-encéphalique monovalents
WO2015107026A1 (fr)	2014-01-15	2015-07-23	F. Hoffmann-La Roche Ag	Variants de région fc présentant des propriétés modifiées de liaison à fcrn et des propriétés conservées de liaison à la protéine a
WO2015112909A1 (fr)	2014-01-24	2015-07-30	Genentech, Inc.	Procédés d'utilisation d'anticorps anti-steap1 et immunoconjugués
WO2015120075A2 (fr)	2014-02-04	2015-08-13	Genentech, Inc.	Mutant smoothened et méthodes d'utilisation de celui-ci
EP3718563A1 (fr)	2014-02-08	2020-10-07	F. Hoffmann-La Roche AG	Procédés de traitement de la maladie d'alzheimer
TW202239429A (zh)	2014-02-08	2022-10-16	美商建南德克公司	治療阿茲海默症之方法
AU2015217271B2 (en)	2014-02-12	2018-10-25	Genentech, Inc.	Anti-Jagged1 antibodies and methods of use
BR112016018980A2 (pt)	2014-02-21	2017-10-10	Genentech Inc	método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica
JP6825909B2 (ja)	2014-02-28	2021-02-03	アラコスインコーポレイテッド	シグレック−８関連疾患を処置するための方法および組成物
MA39746A (fr)	2014-03-14	2021-04-28	Hoffmann La Roche	Compositions de sécrétion de polypeptides hétérologues et procédés associés
WO2015140591A1 (fr)	2014-03-21	2015-09-24	Nordlandssykehuset Hf	Anticorps anti-cd14 et leurs utilisations
BR112016021383A2 (pt)	2014-03-24	2017-10-03	Genentech Inc	Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
WO2015153514A1 (fr)	2014-03-31	2015-10-08	Genentech, Inc.	Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
EP3632934A1 (fr)	2014-03-31	2020-04-08	F. Hoffmann-La Roche AG	Anticorps anti-ox40 et procédés d'utilisation
WO2015164615A1 (fr)	2014-04-24	2015-10-29	University Of Oslo	Anticorps anti-gluten et leurs utilisations
MX2016015162A (es)	2014-05-22	2017-03-03	Genentech Inc	Anticuerpos anti - gpc3 e inmunoconjugados.
CN106661622B (zh)	2014-05-23	2020-08-21	豪夫迈·罗氏有限公司	Mit生物标志物和使用它们的方法
JP2017526618A (ja)	2014-06-11	2017-09-14	ジェネンテック，インコーポレイテッド	抗ＬｇＲ５抗体及びその使用
JP2017517552A (ja)	2014-06-13	2017-06-29	ジェネンテック，インコーポレイテッド	抗癌剤耐性の治療及び防止方法
KR20170026362A (ko)	2014-06-26	2017-03-08	에프. 호프만-라 로슈 아게	항-ｂｒｄｕ 항체 및 사용 방법
JP6451119B2 (ja) *	2014-07-17	2019-01-16	東ソー株式会社	抗体依存性細胞傷害活性の強さに基づき抗体を分離する方法
US10815289B2 (en) *	2014-06-27	2020-10-27	Tosoh Corporation	Fc-binding protein, method for producing said protein, antibody adsorbent using said protein, and method for separating antibody using said adsorbent
EP3166974A1 (fr)	2014-07-11	2017-05-17	Genentech, Inc.	Anticorps anti-pd-l1 et leurs utilisations
EP3166627A1 (fr)	2014-07-11	2017-05-17	Genentech, Inc.	Inhibition de la voie de signalisation notch
AU2015293949B2 (en)	2014-07-21	2019-07-25	Teknologian Tutkimuskeskus Vtt Oy	Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
AU2015308818B2 (en)	2014-08-28	2021-02-25	Bioatla Llc	Conditionally active chimeric antigen receptors for modified T-cells
TWI751102B (zh)	2014-08-28	2022-01-01	美商奇諾治療有限公司	對ｃｄ１９具專一性之抗體及嵌合抗原受體
EA201790545A1 (ru)	2014-09-12	2017-07-31	Дженентек, Инк.	Антитела и иммуноконъюгаты против her2
EP3191518B1 (fr)	2014-09-12	2020-01-15	Genentech, Inc.	Anticorps anti-b7-h4 et immunoconjugués
US9751946B2 (en)	2014-09-12	2017-09-05	Genentech, Inc.	Anti-CLL-1 antibodies and immunoconjugates
JP6730261B2 (ja)	2014-09-17	2020-07-29	ジェネンテック，インコーポレイテッド	抗ｈｅｒ２抗体を含む免疫複合体
PL3262071T3 (pl)	2014-09-23	2020-08-10	F. Hoffmann-La Roche Ag	Sposób stosowania immunokoniugatów anty-CD79b
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
WO2016061389A2 (fr)	2014-10-16	2016-04-21	Genentech, Inc.	Anticorps anti-alpha-synucléine et leurs méthodes d'utilisation
EP3223865A4 (fr)	2014-10-31	2018-10-03	Jounce Therapeutics, Inc.	Méthodes de traitement d'états pathologiques avec des anticorps qui se lient à b7-h4
CN114381521A (zh)	2014-11-03	2022-04-22	豪夫迈·罗氏有限公司	用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
CA2966523A1 (fr)	2014-11-03	2016-05-12	Genentech, Inc.	Tests de detection de sous-ensembles immunitaires de cellules t et leurs procedes d'utilisation
CA2961439A1 (fr)	2014-11-05	2016-05-12	Genentech, Inc.	Anticorps anti-fgfr2/3 et procedes d'utilisation de ceux-ci
RU2017119428A (ru)	2014-11-06	2018-12-06	Дженентек, Инк.	Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
CA2960797A1 (fr)	2014-11-06	2016-05-12	F. Hoffmann-La Roche Ag	Variants du fragment fc caracterises par une liaison fcrn modifiee et leurs procedes d'utilisation
AR102522A1 (es)	2014-11-06	2017-03-08	Hoffmann La Roche	Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a
EP3552488A1 (fr)	2014-11-10	2019-10-16	F. Hoffmann-La Roche AG	Modèle animal pour une néphropathie et agents pour la traiter
CR20170240A (es)	2014-11-10	2018-04-03	Genentech Inc	Anticuerpos anti-interleucina-33 y sus usos
EP3218397B8 (fr)	2014-11-14	2021-04-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps neutralisants contre ebola glycoprotein et leur utilisation
WO2016081384A1 (fr)	2014-11-17	2016-05-26	Genentech, Inc.	Polythérapie comprenant des agonistes se liant à ox40 et des antagonistes se liant à l'axe pd-1
US11008403B2 (en)	2014-11-19	2021-05-18	Genentech, Inc.	Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
US10508151B2 (en)	2014-11-19	2019-12-17	Genentech, Inc.	Anti-transferrin receptor antibodies and methods of use
WO2016081639A1 (fr)	2014-11-19	2016-05-26	Genentech, Inc.	Anticorps contre bace1 et utilisation de ceux-ci pour l'immunothérapie contre les maladies neurales
BR112017010324A2 (pt)	2014-11-20	2018-05-15	F. Hoffmann-La Roche Ag	método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
MX2017006997A (es)	2014-12-01	2017-10-16	Amgen Inc	Proceso para manipular el nivel de contenido de glicano de una glicoproteina.
JP6751393B2 (ja)	2014-12-03	2020-09-02	ジェネンテック，インコーポレイテッド	抗ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗体リファマイシン抱合体及びその使用
EP3227332B1 (fr)	2014-12-03	2019-11-06	F.Hoffmann-La Roche Ag	Anticorps multi-spécifiques
KR20170086536A (ko)	2014-12-03	2017-07-26	제넨테크, 인크.	항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
US9975949B2 (en)	2014-12-05	2018-05-22	Genentech, Inc.	Anti-CD79b antibodies and methods of use
RU2017120039A (ru)	2014-12-10	2019-01-10	Дженентек, Инк.	Антитела к рецепторам гематоэнцефалического барьера и способы их применения
RU2746356C2 (ru)	2014-12-19	2021-04-12	Чугаи Сейяку Кабусики Кайся	Антитела к с5 и способы их применения
WO2016111947A2 (fr)	2015-01-05	2016-07-14	Jounce Therapeutics, Inc.	Anticorps inhibiteurs d'interactions de tim-3:lilrb2 et leurs utilisations
US20160208018A1 (en)	2015-01-16	2016-07-21	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for ror1
WO2016117346A1 (fr)	2015-01-22	2016-07-28	Chugai Seiyaku Kabushiki Kaisha	Combinaison de deux anticorps anti-c5 ou plus et ses procédés d'utilisation
US10330683B2 (en)	2015-02-04	2019-06-25	Genentech, Inc.	Mutant smoothened and methods of using the same
KR20170110129A (ko)	2015-02-05	2017-10-10	추가이 세이야쿠 가부시키가이샤	이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
US10301377B2 (en)	2015-02-24	2019-05-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
MX2017011486A (es)	2015-03-16	2018-06-15	Genentech Inc	Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
WO2016146833A1 (fr)	2015-03-19	2016-09-22	F. Hoffmann-La Roche Ag	Biomarqueurs de résistance à la nad(+)-diphtamide adp-ribosyltransférase
HUE049081T2 (hu)	2015-03-20	2020-09-28	The United States Of America As	GP120 elleni neutralizáló antitestek és alkalmazásuk
SI3273992T1 (sl)	2015-03-23	2020-09-30	Jounce Therapeutics, Inc.	Protitelesa proti ICOS
US10472412B2 (en)	2015-03-25	2019-11-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bispecific multivalent fusion proteins
JP6903587B2 (ja)	2015-04-03	2021-07-14	ユーリカセラピューティックス，インコーポレイテッド	Ａｆｐペプチド／ｍｈｃ複合体を標的化する構築物およびその使用
JP7044553B2 (ja)	2015-04-24	2022-03-30	ジェネンテック，インコーポレイテッド	結合ポリペプチドを含む細菌を特定する方法
JP2018520642A (ja)	2015-05-01	2018-08-02	ジェネンテック，インコーポレイテッド	マスク抗ｃｄ３抗体及びその使用方法
WO2016179194A1 (fr)	2015-05-04	2016-11-10	Jounce Therapeutics, Inc.	Lilra3 et son procédé d'utilisation
EP4238994A3 (fr)	2015-05-11	2024-02-07	F. Hoffmann-La Roche AG	Compositions et méthodes de traitement de la néphropathie lupique
ES2835866T3 (es)	2015-05-12	2021-06-23	Hoffmann La Roche	Procedimientos terapéuticos y de diagnóstico para el cáncer
WO2016196381A1 (fr)	2015-05-29	2016-12-08	Genentech, Inc.	Méthylation de promoteur de pd-l1 dans le cancer
EP3302563A1 (fr)	2015-05-29	2018-04-11	H. Hoffnabb-La Roche Ag	Anticorps contre la glycoprotéine du virus ebola humanisés et procédés d'utilisation
KR20180012753A (ko)	2015-05-29	2018-02-06	제넨테크, 인크.	암에 대한 치료 및 진단 방법
CN107810012A (zh)	2015-06-02	2018-03-16	豪夫迈·罗氏有限公司	使用抗il‑34抗体治疗神经疾病的组合物和方法
WO2016196975A1 (fr)	2015-06-03	2016-12-08	The United States Of America, As Represented By The Secretary Department Of Health & Human Services	Anticorps neutralisants dirigés contre la protéine d'enveloppe (env) du vih-1 et leur utilisation
CN107849124B (zh)	2015-06-05	2021-09-24	基因泰克公司	抗tau抗体及使用方法
EP3303399A1 (fr)	2015-06-08	2018-04-11	H. Hoffnabb-La Roche Ag	Méthodes de traitement du cancer au moyen d'anticorps anti-ox40
CA2988420A1 (fr)	2015-06-08	2016-12-15	Genentech, Inc.	Methodes destinees a traiter le cancer a l'aide d'anticorps anti-ox40 et d'antagonistes se liant a l'axe pd-1
JP2018524295A (ja)	2015-06-15	2018-08-30	ジェネンテック，インコーポレイテッド	抗体及び免疫複合体
CN107847568B (zh)	2015-06-16	2022-12-20	豪夫迈·罗氏有限公司	抗cll-1抗体和使用方法
WO2016204966A1 (fr)	2015-06-16	2016-12-22	Genentech, Inc.	Anticorps anti-cd3 et leurs méthodes d'utilisation
TWI731861B (zh)	2015-06-16	2021-07-01	美商建南德克公司	FcRH5之人源化及親和力成熟抗體及使用方法
MX2017016353A (es)	2015-06-17	2018-05-02	Genentech Inc	Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos.
JP2018524312A (ja)	2015-06-17	2018-08-30	ジェネンテック，インコーポレイテッド	抗ｈｅｒ２抗体及び使用方法
JP6846362B2 (ja)	2015-06-17	2021-03-24	アラコスインコーポレイテッド	線維性疾患を処置するための方法および組成物
DK3313879T3 (da)	2015-06-24	2022-03-14	Hoffmann La Roche	Anti-transferrinreceptor-antistoffer med tilpasset affinitet
JP2018520153A (ja)	2015-06-29	2018-07-26	ジェネンテック，インコーポレイテッド	臓器移植における使用のためのｉｉ型抗ｃｄ２０抗体
ES2898065T3 (es)	2015-06-29	2022-03-03	Ventana Med Syst Inc	Materiales y procedimientos para realizar ensayos histoquímicos para proepirregulina y anfirregulina humanas
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3341415B1 (fr)	2015-08-28	2021-03-24	H. Hoffnabb-La Roche Ag	Anticorps anti-hypusine et leurs utilisations
CA2999369C (fr)	2015-09-22	2023-11-07	Spring Bioscience Corporation	Anticorps anti-ox40 et leurs utilisations diagnostiques
WO2017053807A2 (fr)	2015-09-23	2017-03-30	Genentech, Inc.	Variants optimisés d'anticorps anti-vegf
WO2017053906A1 (fr)	2015-09-24	2017-03-30	Abvitro Llc	Compositions d'anticorps anti-vih et méthodes d'utilisation
MA43345A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
EP3150636A1 (fr)	2015-10-02	2017-04-05	F. Hoffmann-La Roche AG	Anticorps multispécifiques tétravalents
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN114014936A (zh)	2015-10-02	2022-02-08	豪夫迈·罗氏有限公司	双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
IL293708A (en)	2015-10-06	2022-08-01	Genentech Inc	A method for treating multiple sclerosis
CA2997809A1 (fr)	2015-10-07	2017-04-13	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps specifiques d'il-7r-alpha pour le traitement la leucemie lymphoblastique aigue
US10968277B2 (en)	2015-10-22	2021-04-06	Jounce Therapeutics, Inc.	Gene signatures for determining ICOS expression
US10604577B2 (en)	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
CN114891102A (zh)	2015-10-29	2022-08-12	豪夫迈·罗氏有限公司	抗变体Fc区抗体及使用方法
EP3184547A1 (fr)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anticorps anti-tpbg et procédés d'utilisation
EP3368074A2 (fr)	2015-10-30	2018-09-05	Hoffmann-La Roche AG	Anticorps et conjugués anti-facteur d
HUE054093T2 (hu)	2015-10-30	2021-08-30	Hoffmann La Roche	Anti-HtrA1 antitestek és azok alkalmazási eljárásai
WO2017079479A1 (fr)	2015-11-03	2017-05-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human	Anticorps neutralisants dirigés contre la protéine gp41 du vih-1 et leur utilisation
JP6998869B2 (ja)	2015-11-08	2022-02-04	ジェネンテック，インコーポレイテッド	多重特異性抗体のスクリーニング方法
RU2021107536A (ru)	2015-11-23	2021-07-02	Файв Прайм Терапьютикс, Инк.	Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
EP3178848A1 (fr)	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Anticorps de type ii contre cd20 pour la reduction de la formation des anticorps contre des médicaments
JP7325186B2 (ja)	2015-12-09	2023-08-14	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体
PL3390442T3 (pl)	2015-12-18	2024-03-18	Chugai Seiyaku Kabushiki Kaisha	Przeciwciała anty-c5 i sposoby ich stosowania
MX2018008347A (es)	2016-01-08	2018-12-06	Hoffmann La Roche	Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3.
WO2017127764A1 (fr)	2016-01-20	2017-07-27	Genentech, Inc.	Traitements à haute dose pour la maladie d'alzheimer
CA3019952A1 (fr)	2016-02-04	2017-08-10	Curis, Inc.	Mutant smoothened et methodes d'utilisation dudit mutant
CN109196121B (zh)	2016-02-29	2022-01-04	基因泰克公司	用于癌症的治疗和诊断方法
TW202248213A (zh)	2016-03-15	2022-12-16	日商中外製藥股份有限公司	使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法
JP6943872B2 (ja)	2016-03-25	2021-10-06	ジェネンテック，インコーポレイテッド	多重全抗体及び抗体複合体化薬物定量化アッセイ
WO2017180864A1 (fr)	2016-04-14	2017-10-19	Genentech, Inc.	Anticorps anti-rspo3 et méthodes d'utilisation de ceux-ci
JP2019515670A (ja)	2016-04-15	2019-06-13	ジェネンテック，インコーポレイテッド	がんをモニタリングし治療するための方法
ES2850428T3 (es)	2016-04-15	2021-08-30	Hoffmann La Roche	Procedimientos de monitorización y tratamiento del cáncer
CA3021086C (fr)	2016-04-15	2023-10-17	Bioatla, Llc	Anticorps anti-axl, fragments d'anticorps et leurs immunoconjugues et utilisations associees
UA123323C2 (uk)	2016-05-02	2021-03-17	Ф. Хоффманн-Ля Рош Аг	Димерний злитий поліпептид
WO2017192589A1 (fr)	2016-05-02	2017-11-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps neutralisants dirigés contre la grippe ha, leur utilisation et leur identification
EP3455252B1 (fr)	2016-05-11	2022-02-23	F. Hoffmann-La Roche AG	Anticorps anti-ténascine modifiés et procédés d'utilisation
SI3455261T1 (sl)	2016-05-13	2023-01-31	Bioatla, Inc.	Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
WO2017201449A1 (fr)	2016-05-20	2017-11-23	Genentech, Inc.	Conjugués anticorps-protac et procédés d'utilisation
JP7022080B2 (ja)	2016-05-27	2022-02-17	ジェネンテック，インコーポレイテッド	部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
EP3252078A1 (fr)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Anticorps de type ii contre cd20 et anticorps bispecifique contre cd20/cd3 pour traitement de cancer
TW201902512A (zh)	2016-06-02	2019-01-16	瑞士商赫孚孟拉羅股份公司	治療方法
CN109563160B (zh)	2016-06-24	2023-02-28	豪夫迈·罗氏有限公司	抗聚泛素多特异性抗体
WO2018014260A1 (fr)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
RU2019104730A (ru)	2016-07-29	2020-08-28	Чугаи Сейяку Кабусики Кайся	Биспецифическое антитело, обладающее повышенной активностью, альтернативной функции кофактора fviii
CN110088133B (zh)	2016-07-29	2023-12-08	朱诺治疗学股份有限公司	抗独特型抗体及相关方法
CN116251182A (zh)	2016-08-05	2023-06-13	中外制药株式会社	用于预防或治疗il-8相关疾病的组合物
JP7250674B2 (ja)	2016-08-08	2023-04-03	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	がんの治療及び診断方法
WO2018045379A1 (fr)	2016-09-02	2018-03-08	Dana-Farber Cancer Institute, Inc.	Composition et méthodes de traitement des déreglements des lymphocytes b
EP3510046A4 (fr)	2016-09-07	2020-05-06	The Regents of the University of California	Anticorps contre des épitopes spécifiques à l'oxydation
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN109689682B (zh)	2016-09-19	2022-11-29	豪夫迈·罗氏有限公司	基于补体因子的亲和层析
KR102557643B1 (ko)	2016-09-23	2023-07-20	제넨테크, 인크.	아토피성 피부염을 치료하기 위한 il-13 길항제의 용도
CN110139873A (zh)	2016-10-03	2019-08-16	朱诺治疗学股份有限公司	Hpv特异性结合分子
CN110139674B (zh)	2016-10-05	2023-05-16	豪夫迈·罗氏有限公司	制备抗体药物缀合物的方法
AU2017339517B2 (en)	2016-10-06	2024-03-14	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
WO2018068201A1 (fr)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Anticorps à domaine unique et ses variants contre ctla-4
EP3532091A2 (fr)	2016-10-29	2019-09-04	H. Hoffnabb-La Roche Ag	Anticorps anti-mic et méthodes d'utilisation
AU2017355401A1 (en)	2016-11-02	2019-05-02	Jounce Therapeutics, Inc.	Antibodies to PD-1 and uses thereof
AU2017361081A1 (en)	2016-11-15	2019-05-23	Genentech, Inc.	Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
AU2017361887B2 (en)	2016-11-21	2019-08-15	Cureab Gmbh	Anti-GP73 antibodies and immunoconjugates
CR20230163A (es)	2016-12-07	2023-07-06	Genentech Inc	ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
AU2017373884A1 (en)	2016-12-07	2019-05-30	Ac Immune Sa	Anti-tau antibodies and methods of their use
EP3551663A1 (fr)	2016-12-12	2019-10-16	H. Hoffnabb-La Roche Ag	Procédés de traitement du cancer à l'aide d'anticorps anti-pd-l1 et d'anti-androgènes
JOP20190134A1 (ar)	2016-12-23	2019-06-02	Potenza Therapeutics Inc	بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
TW201825515A (zh)	2017-01-04	2018-07-16	美商伊繆諾金公司	Ｍｅｔ抗體以及其免疫結合物及用途
TW201831517A (zh)	2017-01-12	2018-09-01	美商優瑞科生物技術公司	靶向組織蛋白h3肽/mhc複合體之構築體及其用途
US11021535B2 (en)	2017-02-10	2021-06-01	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
AR110873A1 (es)	2017-02-10	2019-05-08	Genentech Inc	Anticuerpos contra triptasa, composiciones de estos y usos de estos
TW201837467A (zh)	2017-03-01	2018-10-16	美商建南德克公司	用於癌症之診斷及治療方法
MX2019011141A (es)	2017-03-22	2019-11-05	Genentech Inc	Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares.
TW202400231A (zh)	2017-03-28	2024-01-01	美商建南德克公司	治療神經退化性疾病之方法
JOP20190203A1 (ar)	2017-03-30	2019-09-03	Potenza Therapeutics Inc	بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
BR112019018767A2 (pt)	2017-04-03	2020-05-05	Hoffmann La Roche	anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção
JP6237948B1 (ja) *	2017-04-04	2017-11-29	住友ベークライト株式会社	糖鎖を調製する方法
MX2019011916A (es)	2017-04-05	2020-01-09	Hoffmann La Roche	Anticuerpos anti-lag3.
MX2019012192A (es)	2017-04-14	2020-01-21	Genentech Inc	Métodos de diagnóstico y terapéuticos para el cáncer.
JP2020517638A (ja)	2017-04-20	2020-06-18	エータイアーファーマ，インコーポレイテッド	肺の炎症を治療するための組成物および方法
JP7248588B2 (ja)	2017-04-21	2023-03-29	ジェネンテック，インコーポレイテッド	疾患の治療のためのｋｌｋ５アンタゴニストの使用
WO2018200586A1 (fr)	2017-04-26	2018-11-01	Eureka Therapeutics, Inc.	Constructions reconnaissant spécifiquement le glypicane 3 et utilisations de ces dernieres
US20220135670A1 (en)	2017-04-27	2022-05-05	Tesaro, Inc.	Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
MX2019013137A (es)	2017-05-05	2020-07-14	Allakos Inc	Metodos y composiciones para tratar enfermedades oculares alergicas.
WO2018209125A1 (fr)	2017-05-10	2018-11-15	Fred Hutchinson Cancer Research Center	Anticorps contre le virus d'epstein-barr, vaccins et leurs utilisations
SG10202112636SA (en)	2017-05-16	2021-12-30	Five Prime Therapeutics Inc	Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
JP2020527351A (ja)	2017-07-21	2020-09-10	ジェネンテック，インコーポレイテッド	がんの治療法及び診断法
EP3658589B1 (fr)	2017-07-26	2023-09-27	Forty Seven, Inc.	Anticorps anti-sirp-alpha et méthodes associées
EP3684413A1 (fr)	2017-09-20	2020-07-29	Chugai Seiyaku Kabushiki Kaisha	Posologie pour polythérapie utilisant des antagonistes de liaison d'axe pd-1 et un agent de ciblage gpc3
CA3080546A1 (fr)	2017-10-03	2019-04-11	Juno Therapeutics, Inc.	Molecules de liaison specifique a l'hpv
CN111372950A (zh)	2017-10-12	2020-07-03	免疫苏醒公司	Vegfr-抗体轻链融合蛋白
CA3080904A1 (fr)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Anticorps et recepteurs antigeniques chimeriques specifiques de l'antigene de maturation des lymphocytes b
JP2021502066A (ja)	2017-11-06	2021-01-28	ジェネンテック，インコーポレイテッド	がんの診断及び療法
KR20200092328A (ko)	2017-12-01	2020-08-03	화이자 인코포레이티드	항-cxcr5 항체 및 그의 조성물 및 용도
EP3724225A1 (fr)	2017-12-15	2020-10-21	Juno Therapeutics, Inc.	Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
MX2020006119A (es)	2017-12-21	2020-08-24	Hoffmann La Roche	Anticuerpos de union a hla-a2/wt1.
EP3728321A1 (fr)	2017-12-22	2020-10-28	F. Hoffmann-La Roche AG	Utilisation d'agents de liaison à pilra pour le traitement d'une maladie
EP4219559A3 (fr)	2017-12-22	2023-10-18	Jounce Therapeutics, Inc.	Anticorps pour lilrb2
KR20200104333A (ko)	2017-12-28	2020-09-03	난징 레전드 바이오테크 씨오., 엘티디.	Tigit에 대한 단일-도메인 항체 및 이의 변이체
KR20200104886A (ko)	2017-12-28	2020-09-04	난징 레전드 바이오테크 씨오., 엘티디.	Pd-l1에 대한 항체 및 변이체
CN111479588A (zh)	2017-12-29	2020-07-31	豪夫迈·罗氏有限公司	用于改善抗vegf抗体的vegf受体阻断选择性的方法
EP3724223A1 (fr)	2018-01-02	2020-10-21	The United States of America, as represented by The Secretary, Department of Health and Human Services	Anticorps neutralisants dirigés contre la glycoprotéine du virus ebola et leur utilisation
EP3735422A1 (fr)	2018-01-05	2020-11-11	AC Immune SA	Molécules de liaison de tdp-43 mal-repliées
US11713353B2 (en)	2018-01-15	2023-08-01	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against PD-1
EP3740505A1 (fr)	2018-01-16	2020-11-25	Lakepharma Inc.	Anticorps bispécifique se liant à cd3 et à une autre cible
PT3743088T (pt)	2018-01-26	2022-12-05	Hoffmann La Roche	Composições il-22 fc e métodos de utilização
MA51676A (fr)	2018-01-26	2021-05-05	Hoffmann La Roche	Protéines de fusion il-22 fc et procédés d'utilisation
CN116041516A (zh)	2018-02-01	2023-05-02	信达生物制药(苏州)有限公司	全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
AU2019218959A1 (en)	2018-02-08	2020-09-03	Genentech, Inc.	Bispecific antigen-binding molecules and methods of use
TWI829667B (zh)	2018-02-09	2024-01-21	瑞士商赫孚孟拉羅股份公司	結合gprc5d之抗體
SG11202007564VA (en)	2018-02-09	2020-09-29	Genentech Inc	Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
CN111757894A (zh)	2018-02-14	2020-10-09	Abba 疗法股份公司	抗人类pd-l2抗体
AU2019226034A1 (en)	2018-02-21	2020-10-15	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to HIV-1 Env and their use
MX2020008502A (es)	2018-02-21	2020-09-25	Genentech Inc	Dosis para el tratamiento con proteinas de fusion il-22 fc.
WO2019165434A1 (fr)	2018-02-26	2019-08-29	Genentech, Inc.	Dosage pour traitement avec des anticorps antagonistes anti-tigit et anti-pd-l1
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
BR112020014591A2 (pt)	2018-03-14	2020-12-01	Beijing Xuanyi Pharmasciences Co., Ltd.	anticorpos anticlaudina 18.2
CA3093729A1 (fr)	2018-03-15	2019-09-19	Chugai Seiyaku Kabushiki Kaisha	Anticorps diriges contre le virus de la dengue presentant une reactivite croisee au virus zika et procedes d'utilisation
AU2019245243A1 (en)	2018-03-29	2020-09-03	Genentech, Inc	Modulating lactogenic activity in mammalian cells
EP3774917A4 (fr)	2018-03-30	2022-01-19	Nanjing Legend Biotech Co., Ltd.	Anticorps à domaine unique contre lag-3 et leurs utilisations
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
CN112566698A (zh)	2018-04-05	2021-03-26	朱诺治疗学股份有限公司	T细胞受体和表达该t细胞受体的工程化细胞
WO2019207159A1 (fr)	2018-04-27	2019-10-31	Fondazione Ebri Rita Levi-Montalcini	Anticorps dirigé contre un peptide neurotoxique dérivé de tau et ses utilisations
ES2955511T3 (es)	2018-05-14	2023-12-04	Werewolf Therapeutics Inc	Polipéptidos de interleucina 2 activables y métodos de uso de los mismos
JP2021524756A (ja)	2018-05-14	2021-09-16	ウェアウルフセラピューティクス，インコーポレイテッド	活性化可能なサイトカインポリペプチド及びその使用方法
US20210221908A1 (en)	2018-06-03	2021-07-22	Lamkap Bio Beta Ltd.	Bispecific antibodies against ceacam5 and cd47
WO2019235426A1 (fr)	2018-06-04	2019-12-12	中外製薬株式会社	Molécule de liaison à un antigène présentant une demi-vie modifiée dans le cytoplasme
WO2019246557A1 (fr)	2018-06-23	2019-12-26	Genentech, Inc.	Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii
WO2020014306A1 (fr)	2018-07-10	2020-01-16	Immunogen, Inc.	Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
CA3104147A1 (fr)	2018-07-18	2020-01-23	Genentech, Inc.	Procedes de traitement du cancer du poumon par un antagoniste de liaison d'axe pd-1, un antimetabolite et un agent a base de platine
AU2019306628A1 (en)	2018-07-20	2021-02-11	Surface Oncology, Inc.	Anti-CD112R compositions and methods
WO2020027330A1 (fr)	2018-08-03	2020-02-06	中外製薬株式会社	Molécule de liaison à l'antigène contenant deux domaines de liaison à l'antigène liés l'un à l'autre
CA3051549A1 (fr)	2018-08-09	2020-02-09	Regeneron Pharmaceuticals, Inc.	Procedes d`evaluation de l`affinite de liaison d`une variante d`anticorps au recepteur fc neonatal
WO2020032230A1 (fr)	2018-08-10	2020-02-13	中外製薬株式会社	Molécule de liaison à l'antigène anti-cd137 et utilisation associée
TW202021618A (zh)	2018-08-17	2020-06-16	美商２３與我有限公司	抗ｉｌ１ｒａｐ抗體及其使用方法
GB201814281D0 (en)	2018-09-03	2018-10-17	Femtogenix Ltd	Cytotoxic agents
EP4268831A2 (fr)	2018-09-12	2023-11-01	Fred Hutchinson Cancer Center	Réduction de l'expression de cd33 pour protéger sélectivement des cellules thérapeutiques
AU2019342099A1 (en)	2018-09-19	2021-04-08	Genentech, Inc.	Therapeutic and diagnostic methods for bladder cancer
EP4249917A3 (fr)	2018-09-21	2023-11-08	F. Hoffmann-La Roche AG	Méthodes de diagnostic du cancer du sein triple négatif
JP2022502088A (ja)	2018-09-27	2022-01-11	エクシリオデベロップメント，インコーポレイテッド	マスクされたサイトカインポリペプチド
EP3858994A4 (fr)	2018-09-28	2022-06-22	Kyowa Kirin Co., Ltd.	Composition d'anticorps
US20220010020A1 (en)	2018-10-05	2022-01-13	Five Prime Therapeutics, Inc.	Anti-FGFR2 Antibody Formulations
WO2020081493A1 (fr)	2018-10-16	2020-04-23	Molecular Templates, Inc.	Protéines de liaison pd-l1
MX2021004348A (es)	2018-10-18	2021-05-28	Genentech Inc	Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
EP3880714A4 (fr)	2018-11-16	2022-07-20	Memorial Sloan Kettering Cancer Center	Anticorps dirigés contre la mucine-16 et leurs procédés d'utilisation
KR20210100656A (ko)	2018-12-05	2021-08-17	제넨테크, 인크.	암 면역요법을 위한 진단 방법 및 조성물
MX2021006573A (es)	2018-12-06	2021-07-15	Genentech Inc	Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20.
CN113227119A (zh)	2018-12-10	2021-08-06	基因泰克公司	用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
AR117327A1 (es)	2018-12-20	2021-07-28	23Andme Inc	Anticuerpos anti-cd96 y métodos de uso de estos
US20220089694A1 (en)	2018-12-20	2022-03-24	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
EP3898667A2 (fr)	2018-12-20	2021-10-27	F. Hoffmann-La Roche AG	Fc d'anticorps modifiés et méthodes d'utilisation
AU2019406712A1 (en)	2018-12-21	2021-06-17	F. Hoffmann-La Roche Ag	Antibody that binds to VEGF and IL-1beta and methods of use
JP2022514950A (ja)	2018-12-21	2022-02-16	２３アンドミー・インコーポレイテッド	抗ｉｌ－３６抗体およびその使用方法
TWI829831B (zh)	2018-12-21	2024-01-21	瑞士商赫孚孟拉羅股份公司	結合cd3之抗體
EP3902833A2 (fr)	2018-12-26	2021-11-03	City of Hope	Protéines de liaison anti-ctla4 masquées activables
CN113272327A (zh)	2018-12-30	2021-08-17	豪夫迈·罗氏有限公司	抗兔cd19抗体及其使用方法
AU2020208193A1 (en)	2019-01-14	2021-07-29	BioNTech SE	Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
JPWO2020153467A1 (ja)	2019-01-24	2021-12-02	中外製薬株式会社	新規がん抗原及びそれらの抗原に対する抗体
PE20212198A1 (es)	2019-01-29	2021-11-16	Juno Therapeutics Inc	Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
GB201901197D0 (en)	2019-01-29	2019-03-20	Femtogenix Ltd	G-A Crosslinking cytotoxic agents
CN113710706A (zh)	2019-02-27	2021-11-26	豪夫迈·罗氏有限公司	用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
MX2021010565A (es)	2019-03-08	2021-10-13	Genentech Inc	Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
MA55296A (fr)	2019-03-14	2022-03-23	Hoffmann La Roche	Traitement du cancer avec des anticorps bispécifiques de her2xcd3 en combinaison avec un mab anti-her2
TW202106876A (zh)	2019-04-19	2021-02-16	日商中外製藥股份有限公司	辨識抗體改變部位之嵌合受體
CN114364703A (zh)	2019-04-19	2022-04-15	豪夫迈·罗氏有限公司	抗mertk抗体及它们的使用方法
AU2020270376A1 (en)	2019-05-03	2021-10-07	Genentech, Inc.	Methods of treating cancer with an anti-PD-L1 antibody
WO2020227228A2 (fr)	2019-05-03	2020-11-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps neutralisants dirigés contre la protéine circumsporozoïte de plasmodium falciparum et leur utilisation
JP2022532217A (ja)	2019-05-14	2022-07-13	ウェアウルフセラピューティクス，インコーポレイテッド	分離部分及びその使用方法
JP2022536602A (ja)	2019-05-14	2022-08-18	ジェネンテック，インコーポレイテッド	濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法
US20230085439A1 (en)	2019-05-21	2023-03-16	University Of Georgia Research Foundation, Inc.	Antibodies that bind human metapneumovirus fusion protein and their use
SG11202112453TA (en)	2019-05-23	2021-12-30	Ac Immune Sa	Anti-tdp-43 binding molecules and uses thereof
MX2022000174A (es)	2019-07-02	2022-05-20	Us Health	Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
AR119382A1 (es)	2019-07-12	2021-12-15	Hoffmann La Roche	Anticuerpos de pre-direccionamiento y métodos de uso
JPWO2021010326A1 (fr)	2019-07-12	2021-01-21
AR119393A1 (es)	2019-07-15	2021-12-15	Hoffmann La Roche	Anticuerpos que se unen a nkg2d
JP2022543553A (ja)	2019-07-31	2022-10-13	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｇｐｒｃ５ｄに結合する抗体
JP2022543551A (ja)	2019-07-31	2022-10-13	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｇｐｒｃ５ｄに結合する抗体
TWI780464B (zh)	2019-08-06	2022-10-11	香港商新旭生技股份有限公司	結合至病理性ｔａｕ種類之抗體及其用途
KR20220062304A (ko)	2019-09-12	2022-05-16	제넨테크, 인크.	루푸스 신장염을 치료하는 조성물과 방법
US20210130492A1 (en)	2019-09-18	2021-05-06	Genentech, Inc.	Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
KR20220066295A (ko)	2019-09-20	2022-05-24	제넨테크, 인크.	항트립타제 항체의 투약
CR20220127A (es)	2019-09-27	2022-05-27	Genentech Inc	Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
JP7413519B2 (ja)	2019-10-18	2024-01-15	ジェネンテック，インコーポレイテッド	びまん性大細胞型ｂ細胞リンパ腫を処置するための抗ｃｄ７９ｂ免疫抱合体の使用方法
US20220389103A1 (en)	2019-11-06	2022-12-08	Genentech, Inc.	Diagnostic and therapeutic methods for treatment of hematologic cancers
EP3831849A1 (fr)	2019-12-02	2021-06-09	LamKap Bio beta AG	Anticorps bispécifiques contre ceacam5 et cd47
JP2023504740A (ja)	2019-12-06	2023-02-06	ジュノーセラピューティクスインコーポレイテッド	Ｂｃｍａ標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
WO2021113780A1 (fr)	2019-12-06	2021-06-10	Juno Therapeutics, Inc.	Anticorps anti-idiotypiques dirigés contre des domaines de liaison ciblant gprc5d et compositions et procédés associés
PE20221511A1 (es)	2019-12-13	2022-10-04	Genentech Inc	Anticuerpos anti-ly6g6d y metodos de uso
PE20221282A1 (es)	2019-12-18	2022-09-05	Hoffmann La Roche	Anticuerpos que se unen a hla-a2/mage-a4
CN113045655A (zh)	2019-12-27	2021-06-29	高诚生物医药(香港)有限公司	抗ox40抗体及其用途
US20230058982A1 (en)	2019-12-27	2023-02-23	Chugai Seiyaku Kabushiki Kaisha	Anti-ctla-4 antibody and use thereof
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
WO2022050954A1 (fr)	2020-09-04	2022-03-10	Genentech, Inc.	Dosage pour traitement avec anticorps antagonistes anti-tigit et anti-pd-l1
WO2021194481A1 (fr)	2020-03-24	2021-09-30	Genentech, Inc.	Dosage pour le traitement avec des anticorps antagonistes anti-tigit et anti-pd-l1
TW202142257A (zh)	2020-01-31	2021-11-16	美商建南德克公司	用ｐｄ－１軸結合拮抗劑及ｒｎａ疫苗誘導新抗原決定基特異性ｔ細胞之方法
CN115768800A (zh)	2020-01-31	2023-03-07	克利夫兰诊所基金会	抗苗勒管激素受体2抗体和使用方法
TW202144395A (zh)	2020-02-12	2021-12-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
US11692038B2 (en)	2020-02-14	2023-07-04	Gilead Sciences, Inc.	Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
WO2021168292A1 (fr)	2020-02-20	2021-08-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps monoclonaux de virus d'epstein-barr et leurs utilisations
CN115151573A (zh)	2020-02-28	2022-10-04	上海复宏汉霖生物技术股份有限公司	抗cd137构建体、多特异性抗体及其用途
WO2021170067A1 (fr)	2020-02-28	2021-09-02	上海复宏汉霖生物技术股份有限公司	Construction anti-cd137 et son utilisation
WO2021183849A1 (fr)	2020-03-13	2021-09-16	Genentech, Inc.	Anticorps anti-interleukine-33 et leurs utilisations
EP4121163A1 (fr)	2020-03-19	2023-01-25	Genentech, Inc.	Anticorps anti-tgf-bêta sélectifs d'isoforme et procédés d'utilisation
CA3169967A1 (fr)	2020-03-24	2021-09-30	Genentech, Inc.	Agents de liaison a tie2 et leurs procedes d'utilisation
JP2023518841A (ja)	2020-03-26	2023-05-08	ジェネンテック，インコーポレイテッド	宿主細胞タンパク質が減少した修飾哺乳動物細胞
WO2021201236A1 (fr)	2020-04-01	2021-10-07	協和キリン株式会社	Composition d'anticorps
CN115698717A (zh)	2020-04-03	2023-02-03	基因泰克公司	癌症的治疗和诊断方法
WO2021207662A1 (fr)	2020-04-10	2021-10-14	Genentech, Inc.	Utilisation d'il-22-fc pour le traitement ou la prévention de la pneumonie, du syndrome de détresse respiratoire aiguë ou du syndrome de libération de cytokines
TW202206111A (zh)	2020-04-24	2022-02-16	美商建南德克公司	使用抗ｃｄ７９ｂ免疫結合物之方法
US20230167198A1 (en)	2020-04-27	2023-06-01	The Regents Of The University Of California	Isoform-independent antibodies to lipoprotein(a)
EP4143345A1 (fr)	2020-04-28	2023-03-08	Genentech, Inc.	Procédés et compositions pour l'immunothérapie du cancer du poumon non à petites cellules
TW202200212A (zh)	2020-05-03	2022-01-01	中國大陸商聯寧（蘇州）生物製藥有限公司	包含抗-trop-2抗體之抗體藥物結合物
CN113993900B (zh)	2020-05-27	2023-08-04	舒泰神（北京）生物制药股份有限公司	特异性识别神经生长因子的抗体及其用途
BR112022024339A2 (pt)	2020-05-29	2022-12-27	23Andme Inc	Anticorpos anti cd200r1 e métodos de uso dos mesmos
CN116529260A (zh)	2020-06-02	2023-08-01	当康生物技术有限责任公司	抗cd93构建体及其用途
EP4157462A1 (fr)	2020-06-02	2023-04-05	Dynamicure Biotechnology LLC	Constructions anti-cd93 et leurs utilisations
US20230340081A1 (en)	2020-06-08	2023-10-26	Hoffmann-La Roche Inc.	Anti-hbv antibodies and methods of use
EP4165415A1 (fr)	2020-06-12	2023-04-19	Genentech, Inc.	Méthodes et compositions pour une immunothérapie anticancéreuse
KR20230025691A (ko)	2020-06-16	2023-02-22	제넨테크, 인크.	삼중 음성 유방암을 치료하기 위한 방법과 조성물
EP4168118A1 (fr)	2020-06-18	2023-04-26	Genentech, Inc.	Traitement avec des anticorps anti-tigit et des antagonistes de liaison à l'axe pd-1
AU2021291407A1 (en)	2020-06-19	2022-09-29	F. Hoffmann-La Roche Ag	Antibodies binding to CD3
AU2021291011A1 (en)	2020-06-19	2023-01-05	F. Hoffmann-La Roche Ag	Antibodies binding to CD3 and CD19
WO2021255146A1 (fr)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Anticorps se liant à cd3 et cea
WO2021255143A1 (fr)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Anticorps se liant à cd3 et folr1
CN116234824A (zh)	2020-06-22	2023-06-06	阿尔米雷尔有限公司	抗il-36抗体及其使用方法
WO2021262783A1 (fr)	2020-06-24	2021-12-30	Genentech, Inc.	Lignées cellulaires résistantes à l'apoptose
CR20230076A (es)	2020-07-10	2023-03-13	Hoffmann La Roche	Anticuerpos que se unen a células cancerosas y dirigen radionucleótidos a dichas células
AU2021308653A1 (en)	2020-07-17	2023-02-16	Genentech, Inc.	Anti-Notch2 antibodies and methods of use
GB2597532A (en)	2020-07-28	2022-02-02	Femtogenix Ltd	Cytotoxic compounds
US20230322935A1 (en)	2020-07-29	2023-10-12	Dynamicure Biotechnology Llc	Anti-cd93 constructs and uses thereof
JP2023536602A (ja)	2020-08-03	2023-08-28	ジェネンテック，インコーポレイテッド	リンパ腫のための診断及び治療方法
EP4192868A1 (fr)	2020-08-05	2023-06-14	Juno Therapeutics, Inc.	Anticorps anti-idiotypiques dirigés contre des domaines de liaison ciblés sur ror1 et compositions et procédés associés
CA3188426A1 (fr)	2020-08-07	2022-02-10	Yichin Liu	Proteines de fusion de ligand flt3 et leurs procedes d'utilisation
TW202221026A (zh)	2020-08-14	2022-06-01	瑞士商Ａｃ免疫有限公司	人源化抗ｔｄｐ－４３結合分子及其用途
EP4208188A1 (fr) *	2020-08-19	2023-07-12	Energesis Pharmaceuticals Inc.	Analogues de facteurs de croissance de fibroblastes humains
EP4204448A2 (fr)	2020-08-27	2023-07-05	cureab GmbH	Anticorps anti-golph2 pour la différenciation des macrophages et des cellules dendritiques
KR20230056766A (ko)	2020-08-28	2023-04-27	제넨테크, 인크.	숙주 세포 단백질의 CRISPR/Cas9 다중 녹아웃
KR20230061458A (ko)	2020-09-04	2023-05-08	에프. 호프만-라 로슈 아게	Vegf-a 및 ang2에 결합하는 항체 및 사용 방법
MX2023002901A (es)	2020-09-14	2023-06-01	Ichnos Sciences SA	Anticuerpos que se unen a la proteína auxiliar del receptor de interleucina-1 (il1rap) y usos de estos.
US11795228B2 (en)	2020-09-30	2023-10-24	Dren Bio, Inc.	Anti-CD94 antibodies and methods of use thereof
CN116406291A (zh)	2020-10-05	2023-07-07	基因泰克公司	用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
JP2023545566A (ja)	2020-10-20	2023-10-30	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｐｄ－１軸結合アンタゴニストとｌｒｒｋ２阻害剤との併用療法
TW202233671A (zh)	2020-10-20	2022-09-01	美商建南德克公司	Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
EP4232475A1 (fr)	2020-10-20	2023-08-30	Kantonsspital St. Gallen	Anticorps ou fragments de liaison à l'antigène se liant spécifiquement à la gremlin-1 et leurs utilisations
WO2022093981A1 (fr)	2020-10-28	2022-05-05	Genentech, Inc.	Polythérapie comprenant des inhibiteurs de ptpn22 et des antagonistes de liaison au pd-l1
EP4240766A2 (fr)	2020-11-04	2023-09-13	Genentech, Inc.	Dosage sous-cutané d'anticorps bispécifiques anti-cd20/anti-cd3
US20220162329A1 (en)	2020-11-04	2022-05-26	Genentech, Inc.	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP2023548064A (ja)	2020-11-04	2023-11-15	ジェネンテック，インコーポレイテッド	抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び抗ｃｄ７９ｂ抗体薬物コンジュゲートによる処置のための投与
TW202237638A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022132904A1 (fr)	2020-12-17	2022-06-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps monoclonaux humains ciblant le sars-cov-2
WO2022140797A1 (fr)	2020-12-23	2022-06-30	Immunowake Inc.	Immunocytokines et utilisations associées
AU2022207615A1 (en)	2021-01-12	2023-07-13	F. Hoffmann-La Roche Ag	Split antibodies which bind to cancer cells and target radionuclides to said cells
EP4277668A1 (fr)	2021-01-13	2023-11-22	F. Hoffmann-La Roche AG	Polythérapie
KR20230147099A (ko)	2021-01-28	2023-10-20	백신벤트 게엠베하	B 세포 매개 면역 반응을 조절하기 위한 방법 및 수단(method and means for modulating b-cell mediated immune responses)
CN117120084A (zh)	2021-01-28	2023-11-24	维肯芬特有限责任公司	用于调节b细胞介导的免疫应答的方法和手段
WO2022162203A1 (fr)	2021-01-28	2022-08-04	Vaccinvent Gmbh	Méthodes et moyens pour moduler des réponses immunitaires à médiation par des lymphocytes b
JP2024509695A (ja)	2021-02-03	2024-03-05	ジェネンテック，インコーポレイテッド	多重特異性結合タンパク質分解プラットフォームおよび使用方法
EP4291306A1 (fr)	2021-02-09	2023-12-20	University of Georgia Research Foundation, Inc.	Anticorps monoclonaux humains dirigés contre des antigènes pneumococciques
US20240117011A1 (en)	2021-02-09	2024-04-11	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Antibodies targeting the spike protein of coronaviruses
JP2024506200A (ja)	2021-02-15	2024-02-09	武田薬品工業株式会社	細胞治療用組成物及びｔｇｆ－ｂシグナル伝達を調節する方法
EP4301781A1 (fr)	2021-03-01	2024-01-10	Xilio Development, Inc.	Combinaison d'anticorps ctla4 et pd1/pdl1 masqués pour le traitement du cancer
TW202317612A (zh)	2021-03-01	2023-05-01	美商艾希利歐發展股份有限公司	用於治療癌症的ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
JP2024509169A (ja)	2021-03-03	2024-02-29	ソレント・セラピューティクス・インコーポレイテッド	抗ｂｃｍａ抗体を含む抗体－薬物コンジュゲート
TW202302646A (zh)	2021-03-05	2023-01-16	美商當康生物科技有限公司	抗vista構築體及其用途
IL305758A (en)	2021-03-10	2023-11-01	Immunowake Inc	Immunomodulatory compounds and their uses
AR125074A1 (es)	2021-03-12	2023-06-07	Genentech Inc	Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
IL305283A (en)	2021-03-15	2023-10-01	Genentech Inc	Compositions and methods for the treatment of lupus nephritis
WO2022197877A1 (fr)	2021-03-19	2022-09-22	Genentech, Inc.	Procédés et compositions pour une libération bio-orthogonale retardée d'agents cytotoxiques
JP2024511424A (ja)	2021-03-25	2024-03-13	ダイナミキュアバイオテクノロジーエルエルシー	抗ｉｇｆｂｐ７構築物およびその使用
AR125344A1 (es)	2021-04-15	2023-07-05	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-c1s
TW202305122A (zh)	2021-04-19	2023-02-01	美商建南德克公司	經修飾之哺乳動物細胞
CN117222412A (zh)	2021-04-23	2023-12-12	豪夫迈·罗氏有限公司	Nk细胞接合剂相关的不良反应的预防或减轻
EP4330282A1 (fr)	2021-04-30	2024-03-06	F. Hoffmann-La Roche AG	Dosage pour un traitement combiné avec un anticorps bispécifique anti-cd20/anti-cd3 et un conjugué anticorps-médicament anti-cd79b
IL308351A (en)	2021-05-12	2024-01-01	Genentech Inc	Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
BR112023023777A2 (pt)	2021-05-14	2024-01-30	Genentech Inc	Anticorpos isolados, composição farmacêutica, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, método para produzir um anticorpo, método para tratar uma condição associada à perda de função de trem2, método para reduzir os níveis de strem2 e uso de um anticorpo
KR20240010469A (ko)	2021-05-21	2024-01-23	제넨테크, 인크.	관심 재조합 생성물의 생성을 위한 변형된 세포
TW202306994A (zh)	2021-06-04	2023-02-16	日商中外製藥股份有限公司	抗ddr2抗體及其用途
KR20240019109A (ko)	2021-06-09	2024-02-14	에프. 호프만-라 로슈 아게	암의 치료에 이용하기 위한 특정 braf 억제제(패러독스 브레이크) 및 pd-1 축 결합 길항제의 조합물
WO2022266660A1 (fr)	2021-06-17	2022-12-22	Amberstone Biosciences, Inc.	Constructions anti-cd3 et utilisations associées
WO2022270612A1 (fr)	2021-06-25	2022-12-29	中外製薬株式会社	Utilisation d'anticorps anti-ctla-4
JP7472405B2 (ja)	2021-06-25	2024-04-22	中外製薬株式会社	抗ｃｔｌａ－４抗体
WO2023283611A1 (fr)	2021-07-08	2023-01-12	Staidson Biopharma Inc.	Anticorps reconnaissant spécifiquement le tnfr2 et leurs utilisations
TW202306985A (zh)	2021-07-12	2023-02-16	美商建南德克公司	降低抗體－脂酶結合之結構
TW202309097A (zh)	2021-07-14	2023-03-01	美商建南德克公司	抗ｃ－ｃ模體趨化因子受體８（ｃｃｒ８）抗體及其使用方法
CN115812082A (zh)	2021-07-14	2023-03-17	舒泰神（北京）生物制药股份有限公司	特异性识别cd40的抗体及其应用
WO2023004386A1 (fr)	2021-07-22	2023-01-26	Genentech, Inc.	Compositions ciblant le cerveau et leurs méthodes d'utilisation
WO2023001884A1 (fr)	2021-07-22	2023-01-26	F. Hoffmann-La Roche Ag	Anticorps de domaine fc hétérodimères
WO2023012147A1 (fr)	2021-08-03	2023-02-09	F. Hoffmann-La Roche Ag	Anticorps bispécifiques et procédés d'utilisation
WO2023019092A1 (fr)	2021-08-07	2023-02-16	Genentech, Inc.	Méthodes d'utilisation d'immunoconjugués anti-cd79b pour traiter un lymphome diffus à grandes cellules b
WO2023019239A1 (fr)	2021-08-13	2023-02-16	Genentech, Inc.	Dosage d'anticorps anti-tryptase
CN117858905A (zh)	2021-08-19	2024-04-09	豪夫迈·罗氏有限公司	多价抗变体fc区抗体及使用方法
WO2023028591A1 (fr)	2021-08-27	2023-03-02	Genentech, Inc.	Méthodes de traitement de pathologie de tau
TW202325727A (zh)	2021-08-30	2023-07-01	美商建南德克公司	抗聚泛素多特異性抗體
AU2022345251A1 (en)	2021-09-17	2024-03-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
TW202321308A (zh)	2021-09-30	2023-06-01	美商建南德克公司	使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
WO2023081818A1 (fr)	2021-11-05	2023-05-11	American Diagnostics & Therapy, Llc (Adxrx)	Anticorps monoclonaux contre des antigènes carcinoembryonnaires et leurs utilisations
WO2023086807A1 (fr)	2021-11-10	2023-05-19	Genentech, Inc.	Anticorps anti-interleukine-33 et leurs utilisations
AR127692A1 (es)	2021-11-16	2024-02-21	Ac Immune Sa	Anticuerpos anti-asc para uso en tratamientos antiinflamatorios
TW202337494A (zh)	2021-11-16	2023-10-01	美商建南德克公司	用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
WO2023094569A1 (fr)	2021-11-26	2023-06-01	F. Hoffmann-La Roche Ag	Polythérapie d'anticorps bispécifiques anti-tyrp1/anti-cd3 et d'anticorps spécifiques de tyrp1
AR127887A1 (es)	2021-12-10	2024-03-06	Hoffmann La Roche	Anticuerpos que se unen a cd3 y plap
WO2023131901A1 (fr)	2022-01-07	2023-07-13	Johnson & Johnson Enterprise Innovation Inc.	Matériaux et procédés de protéines de liaison à il-1beta
US20230322958A1 (en)	2022-01-19	2023-10-12	Genentech, Inc.	Anti-Notch2 Antibodies and Conjugates and Methods of Use
WO2023154824A1 (fr)	2022-02-10	2023-08-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps monoclonaux humains ciblant largement les coronavirus
TW202342519A (zh)	2022-02-16	2023-11-01	瑞士商Ａｃ免疫有限公司	人源化抗ｔｄｐ－４３結合分子及其用途
TW202342520A (zh)	2022-02-18	2023-11-01	美商樂天醫藥生技股份有限公司	抗計畫性死亡配體１（ｐｄ—ｌ１）抗體分子、編碼多核苷酸及使用方法
WO2023173026A1 (fr)	2022-03-10	2023-09-14	Sorrento Therapeutics, Inc.	Conjugués anticorps-médicament et leurs utilisations
TW202346365A (zh)	2022-03-23	2023-12-01	瑞士商赫孚孟拉羅股份公司	抗ｃｄ２０／抗ｃｄ３雙特異性抗體及化學療法之組合治療
WO2023192827A1 (fr)	2022-03-26	2023-10-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps bispécifiques à enveloppe du vih-1 et leur utilisation
WO2023192881A1 (fr)	2022-03-28	2023-10-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps neutralisants dirigés contre la protéine d'enveloppe (env) du vih-1 et leur utilisation
WO2023191816A1 (fr)	2022-04-01	2023-10-05	Genentech, Inc.	Dosage pour traitement avec des anticorps bispécifiques anti-fcrh5/anti-cd3
WO2023194565A1 (fr)	2022-04-08	2023-10-12	Ac Immune Sa	Molécules de liaison anti-tdp-43
US20230406930A1 (en)	2022-04-13	2023-12-21	Genentech, Inc.	Pharmaceutical compositions of therapeutic proteins and methods of use
WO2023198727A1 (fr)	2022-04-13	2023-10-19	F. Hoffmann-La Roche Ag	Compositions pharmaceutiques à base d'anticorps bispécifiques anti-cd20/anti-cd3 et procédés d'utilisation
WO2023203177A1 (fr)	2022-04-20	2023-10-26	Kantonsspital St. Gallen	Anticorps ou fragments de liaison à l'antigène se liant de manière spécifique à gremlin-1 et à gremlin-2 et leurs utilisations
WO2023215737A1 (fr)	2022-05-03	2023-11-09	Genentech, Inc.	Anticorps anti-ly6e, immunoconjugués et leurs utilisations
WO2023219613A1 (fr)	2022-05-11	2023-11-16	Genentech, Inc.	Dosage pour le traitement avec des anticorps bispécifiques anti-fcrh5/anti-cd3
WO2023217933A1 (fr)	2022-05-11	2023-11-16	F. Hoffmann-La Roche Ag	Anticorps se liant à vegf-a et à il6 et méthodes d'utilisation
WO2023235699A1 (fr)	2022-05-31	2023-12-07	Jounce Therapeutics, Inc.	Anticorps dirigés contre lilrb4 et leurs utilisations
WO2023240058A2 (fr)	2022-06-07	2023-12-14	Genentech, Inc.	Méthodes pronostiques et thérapeutiques pour le cancer
WO2023237706A2 (fr)	2022-06-08	2023-12-14	Institute For Research In Biomedicine (Irb)	Anticorps inter-spécifiques, utilisations et procédés de découverte de ceux-ci
WO2024015897A1 (fr)	2022-07-13	2024-01-18	Genentech, Inc.	Dosage pour traitement avec anticorps bispécifiques anti-fcrh5/anti-cd3
WO2024020407A1 (fr)	2022-07-19	2024-01-25	Staidson Biopharma Inc.	Anticorps reconnaissant spécifiquement l'atténuateur de lymphocytes b et t (btla) et leurs utilisations
WO2024020432A1 (fr)	2022-07-19	2024-01-25	Genentech, Inc.	Dosage pour traitement avec des anticorps bispécifiques anti-fcrh5/anti-cd3
WO2024020564A1 (fr)	2022-07-22	2024-01-25	Genentech, Inc.	Molécules de liaison à l'antigène anti-steap1 et leurs utilisations
WO2024030829A1 (fr)	2022-08-01	2024-02-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps monoclonaux se liant à la face inférieure de la neuraminidase virale de la grippe
WO2024028731A1 (fr)	2022-08-05	2024-02-08	Janssen Biotech, Inc.	Protéines de liaison de récepteur de transferrine pour traitement de tumeurs cérébrales
WO2024028732A1 (fr)	2022-08-05	2024-02-08	Janssen Biotech, Inc.	Constructions de liaison à cd98 pour le traitement de tumeurs cérébrales
WO2024037633A2 (fr)	2022-08-19	2024-02-22	Evive Biotechnology (Shanghai) Ltd	Formulations comprenant g-csf et leurs utilisations
WO2024044779A2 (fr)	2022-08-26	2024-02-29	Juno Therapeutics, Inc.	Anticorps et récepteurs antigéniques chimériques spécifiques d'un ligand 3 de type delta (dll3)
WO2024049949A1 (fr)	2022-09-01	2024-03-07	Genentech, Inc.	Méthodes thérapeutiques et diagnostiques pour cancer de la vessie
WO2024054929A1 (fr)	2022-09-07	2024-03-14	Dynamicure Biotechnology Llc	Constructions anti-vista et leurs utilisations
WO2024054822A1 (fr)	2022-09-07	2024-03-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps du sars-cov -2 modifiés ayant une largeur de neutralisation accrue
WO2024064826A1 (fr)	2022-09-22	2024-03-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticorps neutralisants dirigés contre la protéine plasmodium falciparum circumsporozoïte et leur utilisation
WO2024077239A1 (fr)	2022-10-07	2024-04-11	Genentech, Inc.	Méthodes de traitement du cancer avec des anticorps anti-récepteur 8 de la chimiokine à motif c-c (ccr8)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997027303A1 (fr) *	1996-01-24	1997-07-31	Toyo Boseki Kabushiki Kaisha	Alpha-1-6 fucosyltransferases
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2275540B1 (fr) *	1999-04-09	2016-03-23	Kyowa Hakko Kirin Co., Ltd.	Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
CA2424602C (fr) *	2000-10-06	2012-09-18	Kyowa Hakko Kogyo Co., Ltd.	Cellules produisant des compositions d'anticorps
US6946292B2 (en) *	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DE102006035254A1 (de) *	2006-07-26	2008-01-31	Francotyp-Postalia Gmbh	Verfahren und Anordnung zum Erzeugen eines Abdrucks

2003
- 2003-04-09 AU AU2003236018A patent/AU2003236018A1/en not_active Abandoned
- 2003-04-09 JP JP2003582297A patent/JPWO2003085119A1/ja active Pending
- 2003-04-09 CA CA002481658A patent/CA2481658A1/fr not_active Abandoned
- 2003-04-09 EP EP03723098A patent/EP1498491A4/fr not_active Withdrawn
- 2003-04-09 WO PCT/JP2003/004504 patent/WO2003085119A1/fr not_active Application Discontinuation
- 2003-04-09 US US10/409,611 patent/US20040259150A1/en not_active Abandoned
2009
- 2009-08-28 US US12/550,160 patent/US8313913B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US8313913B2 (en)	2012-11-20
EP1498491A1 (fr)	2005-01-19
US20040259150A1 (en)	2004-12-23
EP1498491A4 (fr)	2006-12-13
US20100092997A1 (en)	2010-04-15
AU2003236018A1 (en)	2003-10-20
CA2481658A1 (fr)	2003-10-16
WO2003085119A1 (fr)	2003-10-16

Legal Events

Date	Code	Title	Description
2006-04-07	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060406
2006-04-26	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060425
2006-06-17	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060616
2007-12-01	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071130
2009-06-03	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090602
2009-07-29	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090728
2009-09-09	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090908

Publication	Publication Date	Title
JP6523404B2 (ja)	2019-05-29	抗体組成物を生産する細胞
US8313913B2 (en)	2012-11-20	Method of enhancing of binding activity of antibody composition to Fcγ receptor IIIa
JP4832719B2 (ja)	2011-12-07	ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
JP4628679B2 (ja)	2011-02-09	Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
JP4997108B2 (ja)	2012-08-08	遺伝子組換え抗体組成物
US20040132140A1 (en)	2004-07-08	Production process for antibody composition
JPWO2003055993A1 (ja)	2005-05-12	Ｃｄ２０に特異的に結合する抗体組成物
JPWO2003084569A1 (ja)	2005-08-11	抗体組成物含有医薬
JPWO2003085107A1 (ja)	2005-08-11	ゲノムが改変された細胞
JPWO2005035583A1 (ja)	2007-11-22	Ｉｌ−５受容体に特異的に結合する抗体組成物
JP2007129903A (ja)	2007-05-31	Ｃｄ１０に特異的に結合する抗体組成物